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SUMMARY
A superfusion system, originally devised to examine dopamine
release from striatal synaptosomes, was adapted to study
nicotine-evoked acetylcholine release from hippocampal synaptosomes,
isolated on sucrose gradients. This evoked acetylcholine release was
low. Modifications to the protocol were made to increase this
response. An enzymic extraction procedure was devised that showed
that most, if not all, the collected radioactivity from the
superfusion system was associated with acetylcholine. This is
3
consistent with the observation that 96.6% of the [ H]choline taken 
up by the synaptosomes was acetylated to acetylcholine.
During the course of these experiments a method for isolating
cortical synaptosomes using Percoll was described. This procedure
was applied to the hippocampus and the cholinergic nature of the
fractions was assessed using the markers: acetylcholinesterase,
3
choline acetyltransferase and [ H]choline uptake. From these
experiments, fraction F4 had the highest cholinergic activity. When
compared with the sucrose-isolated synaptosomes, fraction F4 had four
to five times greater response to nicotine in the superfusion system,
3
which was consistent with the six fold higher [ H]choline uptake.
The subcellular content of the fractions from both the sucrose and 
Percoll gradients were examined by electron microscopy.
Nicotine evoked acetylcholine release, from Percoll fraction F4 
synaptosomes, in a dose-dependent manner. This release was Ca++ 
dependent and sensitive to the nicotinic antagonist
dihydroflerythroidine indicating that the response was mediated via the 
nicotinic acetylcholine receptor located on the presynaptic nerve
Vterminals. In view of their therapeutic use in Alzheimer's disease, 
the effect of the acetylcholinesterase inhibitors: BW284C51,
physostigmine and 9, amino 1,2,3,4-tetrahydroacridine, on basal and 
evoked acetylcholine release was examined. The results showed that 
these drugs had more than a purely anticholinesterase action as they 
appear to interact with either the nicotinic acetylcholine receptor 
or other ion channels.
Preliminary extracellular electrophysiological recordings from 
the hippocampal site confirmed that functional presynaptic nicotinic 
acetylcholine receptors are present.
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The hippocampus, situated in the subcortex of the brain was 
first named by Arantius (1587) who was a student of Vesalius:
"At the base of these ventricles which face inward 
toward the median line, an elevation of white 
substance rises up and, as it were, grows there.
This is raised up from the inferior surface like an 
appendage and is continuous with the psalloid body 
or hyra. In its length it extends towards the 
anterior parts and the front of the brain, and is 
provided with a flexous figure of varying 
thickness. This recalls the image of a 
hippocampus, that is of a little sea-horse."
Arantius, 1587.
It took another 200 years before the term hippocampus was adopted.
The comparison with a sea horse is confusing as it is not clear which 
end of the structure represents the animal's head. During this time 
this brain region was also described as a "stout silk worm", Ram's or 
Ammon's horn. The comparison with a horn was disputed because horns 
taper from their roots whereas the hippocampus begins narrow and 
becomes clubbed. However, it is the sea horse that has survived as 
the comparable label for this brain region, the hippocampus.
31.1.2 The cholinergic system, learning and memory
1.1.2.1 The cholinergic synapse
The neurotransmitter acetylcholine (ACh) is synthesised from 
choline (Ch) and acetyl Coenzyme A (AcCoA) by choline 
acetyltransferase (ChAT; EC:2.3.1.6) in the cytoplasm of nerve 
terminals. The acetyl moiety comes from glucose and pyruvate which 
is converted to AcCoA by pyruvate dehydrogenase (PDH; EC:1.2.4.1) in 
the mitochondria. Several proposals have been put forward to explain 
how AcCoA crosses the mitochondrial membrane to the cytoplasm for ACh 
synthesis (see Tucek, 1985). One mode of thought is that AcCoA, 
together with oxaloacetate, is converted to citrate by citrate 
synthase (EC:4.1.3.7) and transported by the tricarboxylic acid 
carrier system to the cytosol where it is converted back to AcCoA by 
ATP citrate lyase (EC:4.1.3.8). The observation that ATP citrate 
lyase blockage by (-)hydroxycitrate reduced ACh synthesis by 40% 
(Endemann & Brunengraber, 1980) shows that citrate is a major source 
of the acetyl moiety of ACh. Another candidate for an acetyl donor 
is acetylcarnitine produced in the mitochondria by carnitine 
acetyltransferase (EC:2.3.1.7). The presence of carnitine 
acetyltransferase in cholinergic nerve terminals was shown by its 
reduction, along with ChAT, after lesions in the septal-hippocampal 
pathway (Tucek, 1985). It has been suggested that AcCoA also crosses 
the membrane directly, in the presence of high Ca++ concentrations 
which increase the permeability of the mitochondrial membrane 
(Benjamin & Quastel, 1981). However, the Ca++ concentrations (ImM) 
needed to increase the membrane permeability are too high to be 
physiologically significant (Ca++ 10- M^ in cytoplasm). There have 
also been reports that AcCoA is produced cytosolically by a PDH
4complex present on the extramitochondrial membrane (Lefresne et al., 
1978) but, so far, no proof of such an extramitochondrial enzyme has 
been obtained by subcellular fractionation studies. Thus it appears 
that AcCoA is first converted to another compound which crosses the 
mitochondrial membrane and is then converted back to AcCoA.
Ch is supplied from dietary intake via the blood, by 
intracellular hydrolysis of phosphatidylcholine or from the reuptake 
of Ch after the breakdown of ACh in the synaptic cleft (see 
fig. 1.1). It was Yamamura & Snyder (1972) who first reported that 
Ch was accumulated, presynaptically, by two kinetically distinct 
processes. The high affinity Ch transport system (HAChT; Kt less 
than or equal to lyM) is Na+ dependent, sensitive to hemicholinium-3 
(HC-3; which blocks Ch uptake) and is associated with a high degree 
of acetylation. The low affinity Ch transporter (LAChT; Kt > 30yM) 
is Na+ independent, needs high HC-3 concentrations to inhibit uptake 
and little of it is acetylated to ACh (Yamamura & Snyder, 1972, 1973; 
Haga & Noda, 1973; Simon et al., 1976). The LAChT has a non-specific 
distribution in the brain (Macintosh & Collier, 1976) and is thought 
to provide Ch for phospholipid synthesis (Meyer et al., 1982). HAChT 
appear to be specific for cholinergic neurones as high affinity 
uptake is reduced with neuronal degeneration after septal-hippocampal 
lesions (Macintosh & Collier, 1976). HAChT was shown to be 
specifically located on cholinergic neurones as ACh synthesis was 
reduced when this uptake system was blocked by low Na+ or HC-3 
(Grewaal & Quastel, 1973; Guyenet et al., 1975). Subsequent reports 
have indicated that HAChT and Ch acetylation to ACh are coupled 
(Barker & Mittag, 1975; Burgess & Prince, 1977) suggesting a membrane 














Fig. 1.1. A schematic diagram of a cholinergic synapse 
depicting Ch uptake, ACh synthesis and release and the ACh receptors. 
AcCoA: acetyl Coenzyme A; ACh: acetylcholine; AChE:
acetylcholinesterase; Ch: choline; ChAT: choline acetyltransferase;
HAChT: high affinity choline transporter; mAChR: muscarinic
acetylcholine receptor; nAChR: nicotinic acetylcholine receptor.
6Carroll, 1981; Meyer et al., 1982).
An influx of Ca++ ions into the nerve terminal will evoke ACh 
release (Miledi, 1973; Crosland et al., 1983). The origin of the 
released ACh was thought to be the synaptic vesicle, which during 
Ca++ influx would fuse with the plasma membrane releasing its quantum 
of transmitter. This process has been debated as both vesicular and 
cytoplasmic ACh pools are present in the nerve terminal (Richter & 
Marchbanks, 1971). Though quantal release is similar to vesicle 
exocytosis no morphological proof for this process has been found 
(Fried & Blaustein, 1978; Dunant, 1986).
Results have shown that newly synthesised cytoplasmic ACh is 
preferentially released with elevated intraterminal Ca++ (Macintosh & 
Collier, 1976; Cunnane, 1984) only if the change in Ca++ was in the 
vicinity of the release site (Vizi & Ashley, 1987). Once released 
ACh interacts with ACh receptors (see section 1.4, fig. 1.1) and is 
then hydrolysed to Ch and acetate by the extracellular enzyme 
acetylcholinesterase (AChE; EC:3.1.1.7) in the synaptic cleft (see 
fig. 1.1). The Ch is then taken up for ACh synthesis to replenish 
transmitter stores.
1.1.2.2. Cholinergic input
The distribution of cholinergic neurones was first attempted by 
staining for the marker enzyme AChE (Shute & Lewis, 1963). However, 
the ubiquitous distribution of AChE, which showed variable densities 
in staining, suggests a low cholinergic specificity of this enzyme. 
Indeed, Koelle (1955) reported that AChE was present in adrenergic 
and other sensory neurones as well as in those cholinergic in nature.
7Thus the presence of AChE alone is not sufficient proof of 
cholinergic innervation (Koelle, 1955; Lehmann & Fibiger, 1979). 
However, the presence of AChE staining and ChAT activity is specific 
for cholinergic neurones (Lewis et al., 1967).
Lewis et al. (1967) used this dual marker procedure to show 
that the hippocampus receives its cholinergic input from the septum. 
After lesioning the neuronal fibres in the septum there was a marked 
reduction in both AChE and ChAT activities in the hippocampus. It is 
now known, from lesion studies, that the cholinergic input into the 
hippocampus originates from the medial septal nucleus and the nucleus 
of the diagonal band (Chronister & Whyte, 1975; Pepeu, 1983), see 
fig. 1.2.
1.1.2.3. Learning and memory
The function of the hippocampus is that of attaining and storage 
of short term memory (Bartus et al., 1982). When the fibres of the 
medial septal nucleus are lesioned (Coyle et al., 1983) or when the 
hippocampus is bilaterally destroyed (Hyman et al., 1984) there is a 
profound and lasting impairment in learning and memory though long 
term memory is retained.
The cholinergic involvement, via the muscarinic and nicotinic 
ACh receptors, in the memory process has been indicated by the fact 
that administration of the muscarinic ACh antagonist, scopolamine, 
reduces cognitive intellectual and memory functions in normal humans 
(Kokman, 1984; Wesnes & Warburton, 1984). These scopolamine induced 
memory impairments are similar to those seen in senile dementia 
(Alzheimer's disease; Davies et al., 1978). The cholinergic agonist,
8MS
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Fig. 1,2. A schematic drawing of the main cholinergic pathways 
in the rat brain (Pepeu, 1983). AM: amygdala; nBM: nucleus basalis
of Meynert; CG: central gray; nDB: nucleus of the diagonal band;
HA: habenula; HI: hippocampus; IPN: interpeduncular nucleus; LH:
lateral hypothalamus; MPO: magnocellular preoptic nucleus; MS:
medial septal nucleus; PPT: peduncolopontine tegmental nucleus; ST:
striatum; TH: thalamus.
9nicotine, has been shown to prevent this scopolamine induced decline 
in memory performance (Wesnes & Warburton, 1984).
1.2 ALZHEIMER'S DISEASE
One disease in which loss of recent memory is a major symptom is 
Alzheimer's disease (Alzheimer, 1907). Historically Alzheimer's 
disease referred exclusively to presenile dementia, where progressive 
memory disorders are seen in patients under 65 years, whereas senile 
dementia applied to older patients (65+ years). As the two 
conditions are clinically, neurologically, pathologically and 
biochemically alike they are now considered to be the same disease 
and routinely referred to as senile dementia of the Alzheimer type 
(SDAT).
1.2.1 Morphology and pathology
The most pronounced and consistent morphological change that 
occurs in SDAT is in the cholinergic system resulting in diffuse 
degeneration of neurones in the neocortex, amygdala and hippocampus, 
as measured by the reduction (60%) in the presynaptic marker enzyme 
ChAT. This reduction in neuronal input is due to atrophy in the 
cholinergic nuclei: the nucleus basalis of Meynert (the origin of
cortical innervation) has a severe reduction in ChAT of up to 75% 
(Whitehouse et al., 1981, 1982; Sitaram, 1984); the hippocampus has 
its cholinergic origins in the medial septal nucleus and the nucleus 
of the diagonal band and these structures have shown 55% and 65% 
reductions in enzyme activity, respectively (Henke & Lang, 1983); see 
fig. 1.2. The validity of using ChAT activity as a marker for the 
disease was shown by Perry et al. (1978) who reported that the
10
reduction in this enzyme was correlated with the extent of 
intellectual impairment in memory information tests.
The pathology is complex and consists of granulov^cular 
degeneration and the presence of senile plaques and neurofibrillary 
tangles. Silver staining techniques have shown the senile plaques to 
be 20-200nm in diameter (Marchbanks, 1982) which consist of abnormal 
axon terminals (derived from cholinergic, adrenergic and 
somatatinergic neurones; Perry & Perry, 1985) and dendritic 
processes, often intermingled with astrocytes and microglial cells, 
associated with a core of extracellular amyloid (Perry et al., 1978; 
Marchbanks, 1982; Coyle et al., 1983). The amyloid protein subunit 
(A4 or 0 protein), encoded on chromosome 21, is an unsoluble highly 
aggregating small polypeptide of 4.5 kilodaltons (kDa; Kang et al.,
1987) which has a high colocalisation with aluminosilicates (Candy 
et al., 1986). This has led to the hypothesis that aluminium may be 
an initiating factor in the disease. However, it is the amyloid 
protein that entraps the aluminium and so elevated aluminium is 
probably secondary in the progression of the disease (McGeer, 1984).
The neurofibrillary tangles, particularly in the perikaryon of 
pyramidal cells, are composed of bundles of tightly packed paired 
helical neurofilaments (10-12nm in diameter), (Marchbanks, 1982;
Coyle et al., 1983). There have been opposing reports on whether the 
correlation between the severity of dementia (and the reduction in 
ChAT) is better mapped to the number of senile plaques (Perry et al., 
1978; Sitaram, 1984) or neurofibrillary tangles (Wilcock & Esiri, 
1982; Wilcock et al., 1982). However, there is a high density of 
both these pathological features in SDAT brain.
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1.2.2. Neurochemistry
The neurochemical changes that take place in SDAT are complex 
and still not completely defined. Enzymic and metabolic markers of 
putative neurotransmitters have been measured in brain tissue, 
obtained from surgical biopsy or autopsy in SDAT and aged matched 
controls (see Corkin, 1981), to assess what neuronal changes have 
taken place. Although the presence of dementia and the densities of 
senile plaques and neurofibrillary tangles correlate best with 
cholinergic abnormalities, alterations in other transmitter systems 
have been reported (for a review see Hardy et al., 1985).
Markers for noradrenergic neurones (noradrenalin; dopamine 0 
hydroxylase; 3-methoxy-4-hydroxyphenylglycol, a metabolite) are 
reduced in the cortex and hippocampus (Adolfsson et al., 1979; Mann 
et al., 1980; Bondareff et al., 1981; Cross et al., 1981, 1983) due 
to degeneration of neurones in the locus coerulus (which project to 
these areas). Reductions in 5-hydroxytryptamine (5HT; serotonin) or 
its metabolite, 5-hydroxy-3-indole acetic acid, have also been shown 
in the cortex, hippocampus and caudate nucleus (Adolfsson et al., 
1979; Cross et al., 1983; Bowen & DaviS0^986). However, there is 
no significant correlation between the clinical and neuropathological 
assessment of the degree of dementia and the monoamine changes, 
suggesting that these effects may be secondary to alterations in the 
cholinergic system (Cross et al., 1983).
Using a radioimmunoassay for the neuropeptide somatostatin there 
was up to 70% reduction in somatostatin-like immunoreactivity in the 
cortex and hippocampus (Davies et al., 1980; Rossor et al., 1980).
The involvement of somatostatin in memory has still to be elucidated
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and so the significance of this reduction remains to be determined 
(McGeer, 1984).
There is no significant change in the GABA-ergic system in SDAT,
in the hippocampus or cortex (Coyle et al., 1984).
The bulk of neurochemical work on brain diseases has
concentrated on measuring transmitter or metabolite levels and/or 
enzyme activities for synthesis or metabolism. Using radiolabelled 
transmitters, agonists or antagonists, changes in receptor densities 
could also be determined (Davies & Verth, 1978). There are two main 
types of ACh receptor. Muscarinic ACh receptors (mAChR) and 
nicotinic ACh receptors (nAChR) so named as muscarine, from the 
fungus Amanita muscaria, and nicotine, a plant alkaloid from 
Nicotiana tobacum, were found to stimulate them selectively (Dale, 
1914). Thus along with assaying for ChAT activity changes in 
receptor binding were also examined in SDAT.
3
Binding experiments using the muscarinic antagonist [ H]QNB
3
(quinuclidinyl benzilate) or [ H]NMS (N-methylscopolamine) have led
to mixed results on the changes in the mAChR in SDAT. Nordberg et
al. (1986) reported a decrease in receptor binding in the cortex
whereas an increase was shown by Nordberg & Winblad (1986). However,
using these ligands other groups have indicated no significant change
in mAChR density in the cortex and hippocampus, compared with age
matched controls (Davies & Verth, 1978; Lang & Henke, 1983; Perry
et al., 1986; Kellar et al., 1987). These results suggest that
mAChRs are predominantly located on postsynaptic neurones (Yamamura &
Snyder, 1974) which are not lost during the disease. Using 
3
[ H]oxotremorine-M, a muscarinic agonist, Mash et al. (1985)
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reported a decrease in ligand binding in SDAT indicating that a 
subtype of mAChR (M2; see section 1.3.1.4.) may be located 
presynaptically and lost with neuronal degeneration.
3 3Using [ Hjnicotine and/or [ H]ACh (in the presence of an AChE
inhibitor, to prevent ACh hydrolysis, and atropine, to block the 
mAChR) there was a marked reduction in nAChR binding sites in the 
hippocampus and cortex of SDAT patients (Flynn & Mash, 1986; Perry 
et al., 1986, 1987; Whitehouse et al., 1986, 1988; Kellar et al., 
1987; Whitehouse & Kellar, 1987; Nordberg et al., 1988). This loss 
of nAChR binding sites correlated with the reduction in ChAT 
(Whitehouse et al., 1986; Kellar et al., 1987; Whitehouse & Kellar,
1987) adding evidence to the suggestion that nAChRs are located 
presynaptically as these receptors would be lost during neuronal 
degeneration.
1.2.3. Therapy
As alterations in the cholinergic system are by far the most 
prominent changes in SDAT, present therapies involve strategies aimed 
at increasing ACh levels to compensate for losses due to neuronal 
degeneration.
One procedure is to prevent ACh breakdown by inhibiting AChE.
The AChE inhibitor physostigmine (eserine) has been reported to 
improve memory in recognition tests (Christie et al., 1981; Davies & 
Mohs, 1982) and reduce the number of inappropriate responses in 
free-recall tasks in SDAT (Anonymous, 1987). However, for 
physostigmine to be an effective treatment, individuals need to be 
carefully titrated to determine the optimal dose as there is a narrow
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therapeutic dose range for memory improvement outside of which there
may be impairment (Davies et al., 1978; Christie et al., 1981;
Hollander et al., 1986). The modest memory enhancement elicited by 
physostigmine is transient as it has a short half life (ti/2 = 30min; 
Anonymous, 1987).
A more persistent AChE inhibitor is THA (9,amino 1,2,3,4 
tetrahydroacridine; t^j = 6-12 hr; Anonymous, 1987) which has 
improved memory in SDAT, when given in conjunction with lecithin 
(Summers et al., 1986). There is, however, considerable excitement 
and controversy over the therapeutic use of THA as it gives rise to 
unacceptable side effects such as liver function disorders, 
diarrhoea, nausea and increased blood pressure (Weintraub & Standish, 
1988). The mode of action of THA has still to be completely defined
but it is more complicated than a simple AChE inhibitor. At
-4 -5 +concentrations of 10 - 10 M THA interacts directly with K
channels (Rogawski, 1987; Stevens & Cotman, 1987), Na+ channels
(Rogawski, 1987) and the nAChR (Perry et al., 1988) and mAChR (Hunter
et al., 1989). As these effects are seen at concentrations much
higher than therapeutic plasma levels of THA (5-70 ng/ml, 10”  ^- 
-810 M; Park et al., 1986) their relevance to the clinical effects of 
THA has still to be determined. However, Perry et al. (1988) did 
report that at therapeutic serum levels THA was still likely to 
interact with the cholinergic, particularly nicotinic, receptor.
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1.3. ACETYLCHOLINE RECEPTORS
An alternative target for therapy is the ACh receptor. The 
postsynaptic mAChR has been studied but as the receptor is not 
altered in SDAT its therapeutic use is limited (McGeer, 1984). 
However, presynaptic receptors whose stimulation would increase ACh 
release, from the reduced numbers of nerve terminals, could be 
targetted.
In the periphery the two types of ACh receptor have opposing 
effects on ACh release from presynaptic nerve terminals. Nicotine 
and its agonists have an excitatory effect on ACh release, which were 
inhibited by nicotinic antagonists (Briggs & Cooper, 1982; Wessler 
et al., 1987) whereas muscarine and its agonists have an inhibitory 
effect on ACh release which can be blocked by muscarinic antagonists 
(Briggs & Cooper, 1982). From this Briggs & Cooper hypothesised that 
the nAChR acts as an accelerator of ACh release, at low ACh 
concentrations, while the mAChR acts as a brake on release, at high 
ACh concentrations, thus achieving fine regulation of ACh release. 
Similar receptor actions have been reported in the CNS (see later). 
The two ACh receptors differ in structure and mechanism of action.
1.3.1. The muscarinic receptor
1.3.1.1. Structure
By sodium dodecyl sulphate polyacrylamide gel electrophoresis 
the mAChR gives a single polypeptide of 70-80 kDa (Birdsall et al., 
1979; Haga & Haga, 1985; Peralta et al., 1987). Sequence analysis, 
electron diffraction and limited proteolysis studies have shown the 
receptor to have a short extracellular glycosylated N-terminal region
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which is thought to be associated with the binding site (Hall, 1987), 
see fig. 1.3a. There are seven hydrophobic regions of 20-25 amino 
acids which span the membrane (Birdsall & Hulme, 1987; Hall, 1987; 
Peralta et al., 1987). Intracellularly there is a long cytoplasmic 
loop between transmembrane regions V and VI that is thought to be the 
site of interaction with G proteins (see later). The cytoplasmic 
hydrophilic C-terminal sequence contains serine and threonine 
residues that can be phosphorylated by protein kinases. This 
phosphorylation may play an important role in desensitisation and 
internalisation of the receptor (Birdsall & Hulme, 1987; Hall, 1987). 
The model (see fig 1.3a) leaves little of the N-terminal structure 
for selective and stereospecific ligand binding so the binding site 
may lie in the pocket formed by the transmembrane domains (Kerlavage 
et al., 1987).
1.3.1.2. Mechanism of action of mAChR
The muscarinic response of the mAChR is slow (latency 100ms and 
300-500ms duration; Sokolovsky & Bartfai, 1981) due to its integrated 
response via three proteins, see fig. 1.3b. The binding of ACh 
initiates the binding of a guanine nucleotide regulatory protein (G 
protein) to the mAChR, which acts as a transducer to an appropriate 
effector system (Bourne, 1986; Hall, 1987). G proteins are a family 
of heterotrimeric proteins: a common 0/y complex (35kDa and lOkDa,
respectively) that is thought to anchor the protein to the 
cytoplasmic face of the membrane and an a chain (41-45kDa) that binds 
GTP and determines the specificity of the G protein for receptor and 







Fig. 1.3 a). The muscarinic receptor arrangement in the lipid 
bilayer showing seven hydrophobic transmembrane spanning regions 
(boxes I-VII) and the extracellular N-terminal and intracellular 
C-terminal.
Fig. 1.3 b). A schematic representation of the arrangement of 
a second messenger receptor mechanism in a membrane.
R: receptor; G: G protein; E: effector.
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Coupling to a receptor causes the G proteins to release GDP and 
bind GTP. The activated G protein can regulate the function of an 
effector, hydrolysis of bound GTP to GDP terminates the regulatory 
effects of the G protein (Bourne, 1986).
The effector that G proteins couple with can be an
enzyme: adenylate cyclase (Gilman, 1984) or phosphatidylinositol 4,5
bisphosphate specific phospholipase C (Berridge & Irvine, 1984).
Coupling of G proteins to these enzymes results in the 
generation of second messengers: either cyclic adenosine
monophosphate or inositol triphosphate and diacylglycerol, 
respectively, which in turn alter the activity of protein kinases 
(Nestler & Greengard, 1983). Phosphorylation by protein kinases 
causes receptor desensitisation and alters the open or closed state 
of a number of ion channels (Christie & North, 1988). Breitweiser & 
Szabo (1985) showed that G proteins can directly bind to K+ channels 
without the intervention of any second messengers (Pfaffinger et al., 
1985). In central neurones, activation of mAChR increases the K+ 
membrane conductance resulting in hyperpolarisation and so inhibiting 
ACh release from presynaptic cells due to reduced action potentials 
(Christie & North, 1988). Alternatively mAChR activation may lead to 
cell depolarisation due to inhibition of K+ conductances (M- 
currents).
1.3.1.3. Location
In the CNS the presynaptic localisation of the mAChR has been 
well documented based on release studies. Muscarinic agonists 
(oxotremorine, carbachol) reduced electrically- or high K+- evoked
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release of ACh from synaptosomes (Nordstrom & Bartfai, 1980; Marchi 
et al., 1981; Raiteri et al., 1984) and slices (Szerb & Somogyi,
1973; Hadhazy & Szerb, 1977) whereas the muscarinic antagonist, 
atropine, restored or enhanced ACh release. Thus there is a 
presynaptic mAChR inhibitory effect on ACh release.
3However, binding studies with the muscarinic antagonist [ HJQNB 
suggested there were only postsynaptic mAChR, as there was no 
reduction in binding after lesions in the medial septal nucleus 
(Yamamura & Snyder, 1974). In 1982, Bowen & Marek showed that the 
classic muscarinic antagonists (QNB, atropine and scopolamine) had a 
10 fold lower affinity for the presynaptic mAChR than the 
postsynaptic. This suggests that the low concentration of QNB (InM) 
used by Yamamura & Snyder may have been too low to detect a
3
presynaptic mAChR effect. Using [ HJdexetimide, a muscarinic 
antagonist, Consolo et al. (1984) reported a 202 reduction in 
receptor binding after septal lesioning supporting the view of a 
presynaptic mAChR.
1.3.1.4. Receptor subtypes
Initially, binding studies with muscarinic antagonists showed a 
single class of binding site (Hulme et al., 1978) but binding studies 
with muscarinic agonists suggested that two major classes of 
receptors which differed widely in their affinities for potent 
agonists. In 1980, Hammer et al. reported that the muscarinic 
antagonist pirenzepine, could discriminate two subclasses of mAChR 
differing in their affinity for pirenzepine by a factor of 20-40. 
Those receptors with a high affinity for pirenzepine (M^ ) had a low 
agonist affinity and were located postsynaptically. The M2 receptor
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had a low affinity for pirenzepine, a high agonist selectively and 
was located both pre- and post-synaptically (Hammer & Giachetti,
1982; Potter et al., 1984). The receptor subtypes also differ in 
tissue location. M^ is predominant in the cortex, hippocampus and 
striatum whereas M2 is predominant in the superior colliculus, 
brainstem, heart and smooth muscle (Potter et al., 1984).
The subtypes of receptor differ also in effector function. The 
M^ (high affinity pirenzepine site) was shown to mediate phosphatidyl 
inositol breakdown (Potter et al., 1984; Gil & Wolfe, 1986) which 
resulted in an accumulation of inositol triphosphate (Kunysz et al.,
1988). Stimulation of M2 (low pirenzepine affinity site) inhibited 
adenylate cyclase (Potter et al., 1984; Gil & Wolfe, 1986).
The receptor subtypes not only differ in location, binding 
properties and effector response but also in DNA sequence. Four 
mAChR sequences have been determined though only two (M^  and M2) have 
so far been expressed (Kerlavage et al., 1987).
1.3.2. The nicotinic receptor
1.3.2.1. Structure
The best characterised nAChR is that obtained from the electric 
organ of Torpedo californica which is a rich source of these 
receptors. The receptor is a pentamer (200-250kDa) composed of (*2^6 
subunits which form a Na+ channel similar to the nAChR of skeletal 
muscle, see fig. 1.4. Under electron microscopy the receptor has a 
diameter of 80 angstroms and a channel 110 angstroms protruding on 
both sides of the membrane (Changeux et al., 1987) which is 6 
angstroms wide at the top and 4 angstroms at the bottom (Oiki et al.,
21
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Fig. 1.4. A schematic diagram of the nicotinic receptor in the 
lipid membrane showing the arrangement of the subunits of the muscle 
receptor.
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1988). Although the individual subunits differ in molecular weight 
(a, 40kDa; 0, 50kDa; yf 60kDa; S, 65kDa) and amino acid sequence the 
overall shape of the folded polypeptide is very similar from one 
subunit to the next (Barnard & Dolly, 1982; Conti-Tronconi & Raftery, 
1982; Noda et al., 1982, 1983; Stevens, 1985).
From cDNA clones of the a subunits the amino acid sequences were
determined (Noda et al., 1982). From the sequence there is a large
extracellular N-terminal and in the a subunit there are cysteines at
positions 192 and 193 which have been shown to be the ACh binding 
site (Karlin et al., 1986). There are four regions of 20 or more 
amino acids that are thought to form a helices that span the lipid 
membrane. Interactions of the hydrophobic groups of the helices with
the hydrophobic environment of the lipid bilayer would stabilise the
protein in the membrane. Structural models predict that each subunit 
would donate one transmembrane helix to form the pore lining of the 
ion channel. Site directed mutations and permeability studies (Dani,
1989) had shown the pore to be composed of the M2 transmembrane 
region which forms an uncharged channel that is surrounded by a net 
negative charge. The M2 region is the most conserved, in the
subunits sequence (Guy & Hucho, 1987), as expected if it is
responsible for nAChR functioning. In the large cytoplasmic loop, 
between transmembrane regions M3 and M4, there is a stretch of 20 
amino acids where every one in four is charged which could twist to 
form an amphipathic helix (MA; Guy, 1984) but, as yet, its function 
has not been determined. Between the M3 and MA, of this cytoplasmic 
region, there is a 20 amino acid stretch of sequence that is rich in 
serine and threonine residues. Phosphorylation at this site, by 
protein kinases, is thought to regulate the rate of receptor
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desensitisation (Goldman et al., 1987).
1.3.2.2. The putative neuronal nicotinic receptor
The study on neuronal nAChR has not progressed as rapidly as 
that of electric organ and muscle due to its lover receptor 
concentration and the concerns about the specificity of a neurotoxins 
used to specifically label muscle nAChR (Morley et al., 1979).
3
In 1974, Eterovic & Bennett reported that [ H]aBGT 
(a-bungarotoxin; a snake venom neurotoxin from Bungarus multicinctus) 
bound to a crude mitochondrial fraction of rat cerebral cortical 
membranes. Thus aBGT was adopted to label neuronal ACh binding 
sites. However, Hunt & Schmidt (1979) shoved the aBGT site, though 
likely to be similar to the nAChR, developed independently of 
cholinergic input and so the usefulness of aBGT in identifying 
cholinergic nAChR was questioned.
Using radiolabelled nicotine Romano & Goldstein (1980) showed 
that ligand binding was stereospecific ((-)nicotine had a 63 fold 
higher affinity for the receptor than (+)nicotine) and this binding 
was not inhibited by aBGT suggesting two binding sites. This view 
was supported by Wonnacott (1986) who reported that the nAChR shoved 
a 88 fold higher affinity for (-)nicotine than (+)nicotine but the 
aBGT binding site was not stereospecific for nicotine. In the 
presence of atropine (to block mAChR) [ H]ACh gave a biphasic binding 
curve indicating the presence of both a high and a low ACh affinity 
binding site (Reuleuke & Hucho, 1985). Thus it appeared that there 
were two ACh receptor ion channels which could be preferentially
labelled with low concentrations of nicotine or aBGT. Regional
3 3distribution of [ HJnicotine or [ H]ACh (plus atropine) and
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125[ I]aBGT, with binding or autoradiographical studies, has shown 
independent binding sites with little overlap between aBGT and 
nicotine (Schwartz et al., 1982; Clarke et al., 1984, 1985) 
suggesting different locations.
Drugs specific for the high affinity ACh binding site (high 
affinity nicotine site) are needed to selectively label the neuronal 
nAChR. One such drug is neuronal bungarotoxin (also known as Toxin 
F, a-bungarotoxin 3.1 or kappa bungarotoxin) whose binding was 
inhibited by the nicotinic antagonists DHpE (dihydro0erythroidine) 
and tubocurarine (Loring & Zigmond, 1988) indicating that binding was 
to the nAChR.
1.3.2.3. Structure of neuronal acetylcholine receptors
The brain aBGT binding site has four subunits (a, 44.7kDa; |3, 
52.3kDa; y, 56.6kDa; 5, 65.2kDa) each encoded on a separate gene and 
has a similar stoichiometry to that of the muscle nAChR 
(Conti-Tronconi et al., 1985; Quik & Geertsen, 1988; see section 
1.3.2.1).
The neuronal nAChR, that has high affinity for nicotine but no 
aBGT binding, consists of only two subunits, a (51kDa) and |3 (79kDa) 
(Whiting et al., 1987). The heavier subunit was called (3 because of 
its slow movement by gel electrophoresis. However, its amino acid 
sequence revealed cysteines at residues 192 and 193 which is 
consistent with the binding site for ACh in the a subunit of muscle 
(Karlin et al., 1986). The stoichiometry of this receptor is not 
known but microsequencing and binding of monoclonal antibodies 
indicate that there is more than one copy of each subunit in the
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receptor (Whiting et al., 1987).
The non ACh binding subunit in the brain nAChR was identified as 
(Deneris et al., 1988) which could substitute for the muscle 0^  to 
form functional receptors in Xenopus oocytes. Using cDNA cloning 
techniques (Wada et al., 1988), (Boulter et al., 1986) and a^  
(Goldman et al., 1987) subtypes have been isolated and are expressed 
as functional receptors when co-injected into Xenopus oocytes with 
the 02 subunit (Boulter et al., 1986; Wada et al., 1988). Thus the 
neuronal nAChR is a heterogenous population of subtypes that differ 
in their distribution as shown by in situ hybridisation (Goldman 
et al., 1987; Deneris et al., 1988). The neuronal subunits have an 
insertion in the cytoplasmic loop between M3 and MA (though 
phosphorylation sites are still present) of varying length and little 
conservation of sequence between subunits (Goldman et al., 1987).
This inserted sequence is thought to be important in directing the 
cellular location of the receptor and could explain how one subtype 
(a^ ) becomes located presynaptically and another (ot^ ) 
postsynaptically. The 02 subunit is coexpressed with c^ , ot^ and a^ .
1.3.2.4. Mechanism of action of nAChR
The nicotinic response, at the neuromuscular junction, has been
well characterised and involves the opening of an ion channel leading
directly to cation flux, thus the response is very rapid
(approximately 10ms). ACh binds to both the a subunits causing an 
allosteric conformational change in the receptor which opens the 
channel to allow cationic influx (Changeux et al., 1984).
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In the CNS, electrophysiological studies have shown a 
physiological response of the nAChR (this is discussed in Chapter 6) 
which also involves cation influx (Aracava et al., 1987) via an ion 
channel (Egan & North, 1986). Rowell & Winkler (1984) reported a 
functional response of the nAChR at the presynaptic nerve terminal of 
the mouse cortex. Nicotine and the agonist DMPP (1,1 
dimethyl-4-phenylpiperazinium) increased the release of newly 
synthesised ACh and this effect was blocked by the nicotinic 
antagonist hexamethonium. A similar nicotinic excitatory effect on 
transmitter release has been reported at the dopamine heteroreceptor 
in the striatum (Rapier et al., 1988) and at the ACh autoreceptor in 
the hippocampus, the subject of this study.
For either muscarinic or nicotinic presynaptic receptors to be 
considered as therapeutic targets in the treatment of SDAT, by 
increasing ACh release, drugs which act as nicotinic agonists (which 
evoke ACh release) or muscarinic antagonists (which enhance evoked 
ACh release by blocking the inhibitory effect of the mAChR) need to 
be found. Indeed, administration of nicotine has been reported to 
enhance memory in patients with SDAT (Sahakian et al., 1989) and 
change in the nAChR correlates better with the density of senile 
plaques than change in ChAT (Perry et al., 1989). Thus, a better 
understanding of the pharmacological characteristics of the nAChR may 
help in the evaluation of the nAChR as a possible therapeutic target 
in SDAT.
27
1.4. SYNAPTOSOMES AS A MODEL SYSTEM FOR PRESYNAPTIC 
STUDIES
When brain tissue is homogenised, in isotonic solution, the 
plasma membrane of the cells are broken at points of highest stress 
or least resistance. The nerve terminals are sheared off from their 
axons. The membrane reseals to form the synaptosome (Whittaker,
1969) containing cytoplasm, with a full complement of glycolytic 
enzymes, synaptic vesicles and one or two mitochondria. Once formed, 
synaptosomes maintain their integrity, given the appropriate osmotic 
conditions, for several hours. They retain most of the structural 
and functional characteristics of nerve terminals. If in a suitable 
balanced salt solution containing an energy source (usually glucose) 
they are metabolically active. They maintain ionic gradients by 
extruding Na+ ions and taking up K+ ions to retain membrane 
potentials (Heaton & Bachelard, 1973). They take up other substances 
like putative transmitters (Bogdanski et al., 1970) or their 
precursors (Dowdall & Simon, 1973) by saturable carrier-mediated, 
Na+-dependent processes. Synaptosomes release transmitter in a Ca++ 
dependent manner when depolarised with high K+ concentrations (Briggs 
& Cooper, 1982; Rapier et al., 1989) or electrically (DeBelleroche & 
Bradford, 1973). Thus most synaptic functions are conserved.
1.4.1. Synaptosomal isolation
Synaptosomes are separated from the cellular debris and other 
subcellular organelles present in the homogenate by differential 
centrifugation. Most methods for synaptosomal isolation are based on 
conventional sucrose density centrifugation (DeRobertis et al., 1962; 
Gray & Whittaker, 1962). First, cell debris and nuclei from the
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homogenate are precipitated by a low speed centrifugation (PI 
pellet). The supernatant (SI) is then recentrifuged, at higher 
speed, to sediment myelin, synaptosomes and mitochondria in a P2 
pellet. The P2 pellet is resuspended and centrifuged on a three step 
sucrose density gradient. Myelin fragments are light and so float on 
0.8M sucrose. Mitochondria have a rich matrix so when exposed to 
dense sucrose undergo osmotic dehydration which allows them to 
penetrate 1.2M sucrose. Synaptosomes are sealed structures and 
osmotically sensitive but rich in cytoplasm and have a higher water 
content than mitochondria so equilibrate between 0.8M and 1.2M 
sucrose.
The hypertonicity of the sucrose causes shrinkage and alteration 
to the cytoskeletal structure (Whittaker, 1969; Day et al., 1971).
The hypertonic sucrose is removed by dilution and centrifugation 
ready for resuspension in ionic medium containing glucose for 
maintenance of metabolism. The ionic medium allows rehydration to a 
more 'natural' appearance.
Many modifications, such as layering the homogenate directly on 
to a two step sucrose gradient (DeBelleroche & Bradford, 1980) or use 
of different isolating media have been tried to improve the 
physiological status of the synaptosomes or their speed of 
centrifugation. Colloidal silica particles (Ludox) were introduced 
as gradient media (Mateyko & Kopac, 1963) but these silica solutions 
were toxic to living cells. Addition of polymers eg 
polyvinylpyrrolidone (PVP) or polyethylene glycol (PEG) increased the 
stability of the colloids and decreased their toxic effects 
(Lagercrantz & Pertoft, 1972). However, the large excess of free
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polymer increased osmolarity and viscosity of the media so making it 
difficult to remove the media from biological membranes.
Hypertonicity of sucrose was overcome by the use of other media 
such as Ficoll/sucrose (Kurokawa et al., 1965; Abdel-Latif, 1966; 
Autilio et al., 1968; Cotman & Matthews, 1971). Ficoll is a high 
molecular weight dextran polymer which is essentially inactive 
osmotically and forms gradients over the same range as sucrose. 
Ficoll/sucrose media increase the viability of the synaptosomes due 
to a shorter centrifugation time. Structural morphology was better 
preserved due to the isotonic isolating conditions and metabolic 
activity was increased (Verity, 1972). However, commercially 
available Ficoll requires extensive dialysis and lyophilisation 
before use. It is more viscous than sucrose so needs higher 
centrifugation speeds to fractionate the P2 pellet. Also Ficoll 
adheres to biological membranes so compromising biochemical studies.
A more recent development is Percoll which is a colloidal 
suspension of silica particles coated with PVP (Pharmacia, 1982). 
Percoll is osmotically inactive and produces isotonic gradients of 
low viscosity enabling more rapid separation with smaller centrifugal 
forces. Nagy & Delgado-Escueta (1984) used a two step Percoll 
gradient (4mls each of 16% and 10% Percoll in 0.25M sucrose 
containing EDTA and HEPES, pH 7.5) to separate the subcellular 
fractions from the P2 pellet. Dunkley et al. (1987) reported that 
sucrose brought to a pH of 7.5 with HEPES, PIPES or Tris caused 
aggregation of membranes thus disrupting normal fractionation so 
sucrose was brought to the desired pH of 7.4 with dilute acid (HC1) 
or alkali (NaOH). The advantages of Percoll are that the procedure
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is fast, as it does not require long centrifugation times, uses an 
innocuous medium, so giving metabolically active synaptosomes of good 
purity, and can be used for small amounts of tissue, an important 
consideration when working on discrete brain regions such as the 
hippocampus.
The synaptosome preparation represents a heterogenous population 
of nerve terminals of mixed origin utilising many different 
transmitters. Using the Percoll protocol of Dunkley et al. (1987,
1988) it may be possible to further purify the synaptosomes into 
transmitter subtypes, as synaptosomes are present in four of the five 
fractions obtained from the four step Percoll gradient (see 
fig. 4.1).
1.4.2. Superfusion
The principle of superfusion is that synaptosomes, brain slices 
or minces, preloaded with radiolabelled transmitter or precursor, are 
continually superfused with a balanced salt solution, containing 
glucose to maintain metabolic activity. The effect of drugs, 
introduced into the system, can be monitored by the release of 
labelled transmitter. Superfusion is a good system to study 
transmitter release from synaptosomes as re-uptake of transmitter is 
minimised by prompt removal of the superfusate.
1.5. AIMS OF THIS REPORT
A better pharmacological profile of the presynaptic nAChR is 
needed before its usefulness as a therapeutic target in SDAT can be 
determined. The presynaptic hippocampal nAChR was characterised 
pharmacologically using a superfusion system whereby the receptor
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response to drugs was monitored by the level of ACh released. The 
effect of AChE inhibitors: THA, physostigmine (both used
therapeutically in SDAT) and BW284C51, on ACh release via the nAChR 
was also observed in the superfusion system.
Preliminary extracellular electrophysiological recordings were 





( H-methyl)choline chloride ([ H]Ch; 80Ci/mmole) and
3 3( H-methyl)acetyl Coenzyme A ([ H])AcCoA; 3Ci/mmole) were obtained
3
from Amersham International (Amersham, Bucks, UK). The [ H]Ch was 
stored at -20°C. The [^H]AcCoA was diluted with Triton X-100 buffer 
(for composition see section 4.2.5) to give a final concentration of 
2mM (specific activity lOyCi/yMol) and stored at -20°C in lOOyl 
aliquots.
(-)Nicotine hydrogen(+)tartrate was purchased from BDH Chemicals 
(Poole, Dorset, UK). Dihydroperythroidine (DHpE) was a gift from Dr. 
Benfield, Merck, Sharp & Dohme Research Laboratory (Hertfordshire, 
UK). (+)Anatoxin-a (ANTX) was donated by Dr. Albuquerque,
Department of Pharmacology and Experimental Therapeutics, University 
of Maryland (Baltimore, USA).
Percoll was obtained from Pharmacia (Sweden).
The acetylcholinesterase inhibitors BW284C51 (1,5 bis(4 allyl 
dimethylammoniumphenyl)pentan3one dibromide) and physostigmine 
(eserine) were obtained from Sigma Chemical Company Ltd. (Poole, 
Dorset, UK). THA (9 amino 1,2,3,4 tetrahydroacridine hydrochloride) 
was a gift from Dr. Perry, Department of Neuropathology, Newcastle 
General Hospital (Newcastle-Upon-Tyne, UK).
All other reagents were supplied by either BDH Chemicals (Poole, 
Dorset, UK), Fisons (Loughborough, Leicestershire, UK) or Sigma 
Chemical Company Ltd. (Poole, Dorset, UK).
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The Krebs buffer, used throughout the experimental procedures, 
was freshly prepared and had a composition (final concentration, mM: 
NaCl, 118; KCl, 2.35; CaCl22H20, 2.40; KH2P04, 1.20; MgS047H20, 1.20; 
NaHCO^, 25; glucose, 10; which was gassed for 1-2 hr, before use, 
with 95% oxygen/5% carbon dioxide to give a pH of 7.4 at room 
temperature.
Unless otherwise stated Optiphase 'Safe' scintillant was used 
for determination of radioactivity in a Packard liquid scintillation 
counter at 4°C giving a counting efficiency of 35-40%.
Statistical analysis of data was carried out using a two tailed 
unpaired Student t-test. Significances of 95% or greater were 
accepted.
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Hippocampal synaptosomes were isolated as described by Rapier 
et al. (1988) whereby the homogenate was layered directly onto a two 
step sucrose gradient. After determining the optimal conditions for
3
labelling the ACh pool with [ H]Ch, the effect of nicotine and other 
3
drugs on [ H]ACh release was studied by superfusion as described by 
Rapier et al. (1988). The released radioactivity was shown to be 
ACh by an enzymic extraction method.
The synaptosome isolation procedure adopted enabled synaptosomes 
to be ready for use after a 1 hr ultracentrifugation and a 7 min 
washing step. Speed of preparation is an important factor, 
considering the subsequent lengthy superfusion process, as functional 
activity of the synaptosomes decreases with time. The conventional 
sucrose gradient centrifugation procedure of Gray & Whittaker (1962) 
takes 3 hr.
The superfusion protocol was devised to monitor nicotine-evoked
3
[ H]dopamine release from rat brain striatal synaptosomes. Rapier 
et al. (1987) had, in preliminary studies, already shown that this 
procedure could be used to measure nicotine-evoked ACh release from 
hippocampal synaptosomes. However, the response to nicotine was 
relatively low making differences in response to subsequent 
stimulations difficult to determine and so the system was adapted in 
order to study the cholinergic nicotinic effects more clearly.
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3.2. METHODS
3.2.1. Synaptosome isolation on a discontinuous sucrose 
gradient
Male Wistar rats (200-250g) were killed by cervical dislocation 
and the brain rapidly removed and placed on filter paper, 
pre-moistened with ice cold 0.32M sucrose (pH 7.4 with dilute NaOH). 
The hippocampus (100-150mg wet weight) was dissected out and 
homogenised (10% w/v in 0.32M sucrose, pH 7.4) in a pre-cooled 
glass-Teflon homogeniser (clearance 0.31mm) by 2 x 6 up and down 
strokes at 200rpm. The homogenate was diluted to 2ml with 0.32M 
sucrose and layered on to two discontinuous sucrose gradients, 
comprised of 1.2M (2ml) and 0.8M (2ml) sucrose, pH 7.4. The
gradients were centrifuged at 100,000g for 1 hr at 4°C in a Beckman
L5-50B ultracentrifuge using a SW50.1 swing out rotor (Rapier et al.,
1988).
The synaptosome fraction at the 0.8M/1.2M sucrose interface (see 
fig. 3.1) was removed with a pasteur pipette and diluted 1:1 with 
Krebs buffer (see materials for composition), mixed by gentle 
pipetting up and down then centrifuged at l,000g for 10 min at room
temperature in a MSE bench centrifuge.
The supernatant was discarded and the pellet gently resuspended 
in Krebs buffer to 10% w/v of the original wet tissue weight. The 












Fig. 3.1. A schematic diagram of the subcellular distribution 
of hippocampal homogenate on a discontinuous sucrose gradient. The 
gradient was centrifuged at 100,000g for 1 hr at 4°C in a Beckman 
L5-50B ultracentrifuge using a SW50.1 swing out rotor.
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3.2.2* Lactate dehydrogenase assay
Lactate dehydrogenase (LDH; EC:1.1.1.27) activity was measured 
in each fraction from the sucrose gradient (see fig. 3.1). LDH is a 
cytoplasmic enzyme which is released only when the synaptosomal 
membrane is disrupted (Johnson & Whittaker, 1963). Thus a measure of 
entrapped (occluded) LDH not only gives an indication of the 
structural integrity of synaptosomes, it is also a means of assessing 
the reproducibility of the subcellular fractionation procedure.
Enzyme activity was assessed by measuring the oxidation of NADH 
in the presence of pyruvate:
A vol in cuvette 1
- x -------------  x - x 10”**
E vol in sample p
where A = change in absorbance/min
3 -1E = molar absorption coefficient (6.22 x 10 Mem )
1 = path length of light (1cm) 
p = protein concentration (mg/ml)
The method used was that of Johnson (1960) as modified by 
Marchbanks (1967) who included the addition of Triton X-100 into the 
experimental protocol to rupture the synaptosomes, thus giving a 
measurement of occluded LDH. The measurements obtained were:
Free LDH : absence of Triton X-100 
Total LDH: presence of Triton X-100 
Occluded LDH = Total LDH - Free LDH
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All reagents used for the assay were freshly prepared. Tris-HCl 
buffer (2.7ml; 0.15M, pH 7.4), sodium pyruvate (0.1ml; lOmM in 
Tris-HCl buffer) and a sample (0.1ml) from the gradient were placed 
in a cuvette in a Pye Unicam SP6-450 spectrophotometer, equipped with 
a chart recorder. The reaction was initiated by the addition of NADH 
(0.1ml; 2mM in Tris-HCl buffer), followed by rapid mixing. Free LDH 
was measured by monitoring the oxidation of NADH at 340nm for at 
least 1 min. Triton X-100 (0.1ml; 102 v/v in Tris-HCl buffer) was 
then added to the cuvette and the change in absorbance at 340nm 
monitored for at least 1 min.
3.2.3. Protein determination
Protein concentrations were obtained using the method of Lowry 
et al. (1951). Standard curves were constructed using a freshly 
prepared solution of bovine serum albumin (BSA) over the 
concentration range 0-350yg/ml.
BSA standards (0.2ml) or fraction from the gradient (0.2ml 
sample diluted 1/10 or 1/20 with distilled water) were incubated with 
alkaline cupric tartrate at room temperature for 10 min. The 
alkaline cupric tartrate was freshly prepared by diluting 1 vol of 12 
(w/v) CuSO^S^O and 1 vol of 22 (w/v) sodium tartrate with 100 vol of 
22 (w/v) ^ 2^2 in 0.1M NaOH. After incubation, Folin-Ciocalteau's 
reagent (0.1ml; diluted 1:1 with distilled water) was added to each 
sample and the colour allowed to develop at room temperature for 40 
min. The blanks contained distilled water (0.2ml) in place of 
protein. The absorbance, at 750nm, was read in a Pye Unicam SP8-100 
spectrophotometer.
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3.2.4. Characterisation of choline uptake
In order to optimally label the synaptosomal ACh pool the 
3
parameters for [ H]Ch uptake were determined.
3.2.4.1. The effect of incubation time
The protocol used follows that described by Marchi et al.
(1983) where the synaptosomal fraction from the sucrose gradient was 
equilibrated at 37°C for 10 min. The [^H]Ch (diluted 1:1 with cold 
choline chloride, 20yM) was added with mixing to give a final 
concentration of 0.8yM (31Ci/mmole). At time intervals (0-60 min) 
samples (0.1ml) were taken and placed on Whatman GFC filters, 
pre-moistened with Krebs buffer, in a Millipore manifold filtration 
unit under gentle suction. The filters were immediately washed with 
5ml Krebs. A sample (lOyl) of the preparation was applied directly 
on to a GFC filter, without suction or washing, to give an estimate 
of the total radioactivity present.
Non-specific Ch uptake was determined in the presence of 
hemicholinium-3 (HC-3; lyM final concentration). At low 
concentrations HC-3 is a specific inhibitor of the Na+-dependent 
HAChT (Guyenet et al., 1973; Haga & Noda, 1973; Yamamura & Snyder, 
1973). Therefore any Ch uptake in the presence of HC-3 will be due 
to non-specific transport systems and passive diffusion into the 
synaptosomes.
Radioactivity was measured in the presence of 5ml scintillant. 
The results were expressed as pmoles Ch taken up/mg protein.
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3.2.4.2. The effect of choline concentration
The effect of Ch concentration on Ch uptake was determined by
3
varying the final concentration of [ H]Ch (0.2-2.0yM) added after a 
10 min pre-equilibration at 37°C. Samples (0.1ml) were filtered 
after a 20 min incubation, as described above. Non-specific uptake 
was determined in the presence of HC-3 (lyM).
Results were expressed as pmoles Ch taken up/mg protein. A 
direct linear plot (Eisenthal & Cornish-Bowden, 1974) was used to 
determine the kinetic parameters of Ch uptake: Kt, the concentration
for half maximal transport, and Vmax, the maximum transport of Ch.
3
The conditions adopted for [ H]Ch uptake, in future experiments, 
were: a 10 min pre-equilibrium period at 37°C followed by a 20 min
incubation, at 37°C, with 0.8pM [^ H]Ch.
3.2.5. The superfusion system
The effect of nicotinic agonists and antagonists on ACh release 
was studied using the superfusion system described by Mills & 
Wonnacott (1984) as modified by Rapier et al. (1988).
The [^H]Ch loaded synaptosomes (20 min at 37°C with 0.8yM
3
[ H]Ch, as above) were washed in an equal vol of Krebs buffer by 
centrifugation (7 min, 3,000g) in a microfuge. The supernatant was
3
discarded thus removing excess [ H]Ch that had not been taken up by
the synaptosomes. The pellet was gently resuspended in Krebs buffer
3
(to original volume for [ H]Ch uptake) and samples (150yl) were taken 
for superfusion.
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Routinely, four superfusion chambers were used. In each case, 
the synaptosome sample was placed on a Whatman GFF filter, 
pre-moistened with Krebs buffer, in the superfusion chamber 
(consisting of a rimmed glass column and a rimmed glass funnel held 
together with a spring clamp, see fig. 3.2). A Whatman GFD 
pre-filter was positioned on top of the synaptosomes before tubing, 
introducing buffer and air pressure, were placed into the chamber. 
Krebs buffer (37°C, continually gassed with 95% oxygen/5% carbon 
dioxide) was pumped onto the filter at a flow rate of 9ml/hr. Air 
pressure (20 p.s.i.) was applied above the filter to ensure rapid 
flow through of superfusate. Each superfusion chamber was placed 
over a LKB 2112 Redirac fraction collector and fractions (8 drops; 
340yl) were collected directly into minivials. To each fraction 3ml 
of scintillant was added before the radioactivity was measured.
After a 40 min washout period, the synaptosomes were stimulated 
at 30 min intervals with a 50yl (40s) pulse of agonist (made up in 
Krebs buffer); three such stimulations were routinely given before a 
fourth stimulation with 20mM K+ was administered. The agonist pulse 
was separated, on either side, from the Krebs washing buffer by an 
air bubble (30s), see below. The responses to successive 
stimulations were designated SI, S2, S3 and S4 and evoked release was 
quantified by summing the radioactivity in the fractions contributing 
to a peak of release, after subtraction of baseline. The baseline, 
due to basal release, was determined by drawing a best fit line 


















Fig. 3.2. A schematic diagram of a superfusion chamber. This 
shows the position of the synaptosomes between GFD and GFF filters at 
the bottom of the chamber.
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BUFFER AGONIST BUFFER
A schematic representation of an agonist pulse separated from the 
Krebs washing buffer by two air bubbles in the tubing of the 
superfusion apparatus.
The effect of antagonists on agonist evoked release was studied 
by removing the tubing from the normal washing Krebs buffer and 
placing it into Krebs buffer containing the antagonist (continually 
gassed as above), 15 min after administration of the SI agonist 
pulse. Subsequent stimulations were carried out with agonist and K+ 
made up in Krebs buffer containing antagonist.
3.2.6. Enzymic separation of [^HJACh from [^HJCh
So far it has been assumed that all the tritium collected from
3
the superfusion system is [ H]ACh. When the synaptosomes are loaded
3 3
with [ H]Ch it is converted to [ HJACh by ChAT and it has been
suggested that ACh, from this newly synthesised pool of ACh is
preferentially released upon stimulation (Macintosh & Collier, 1976;
Cunnane, 1984). However, some of the radioactivity collected could
be due to [^HJCh which:
1. had not been removed during washing
2. had leaked from synaptosomes before it had been acetylated by 
ChAT
3
3. was present due to the breakdown of released [ HJACh by AChE 
present on the external membranes of synaptosomes (J^clntosh 
& Plummer, 1976).
46
A method which could be used routinely to differentiate between 
3 3[ H]ACh and [ H]Ch was devised based on that described by Goldberg & 
McCaman (1973). This enzymic extraction procedure could be carried 
out in the minivials in which the superfusion samples were collected.
The basis of the enzymic extraction protocol is as follows and 


















organic phase [ HJACh counted 
3
aqueous phase P-[ HJCh not counted
where ATP = adenosine triphosphate
ChK = choline kinase (EC: 2.7.1.32) 
TPB = tetraphenylboron 
PPO = 2,5,diphenyloxazole
3.2.7. Synthesis of [3H]ACh
Before determining the parameters of the enzymic extraction
3
procedure [ HJACh was synthesised to use as a standard in the
3
protocol. This was accomplished by the acetylation of [ HJCh with 
acetic anhydride, as described by Schuberth & Sundwall (1967).
3[ HJCh (0.1ml; lOOpCi) was evaporated to dryness before acetic 
anhydride (0.2ml) was added, mixed and incubated at 37°C for 24 hr. 
Excess anhydride was evaporated and the residue was washed twice with
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analar methanol (0.1ml; 95%). The acetic anhydride incubation and 
the methanol washes were repeated to ensure complete acetylation.
37°C, 24 hr
(ch3)3n+ch2ch2oh + ch3co-o-occh3 -------------->
choline + acetic anhydride
(ch3)3n+ch2ch2-o-och3 + ch3cooh
acetylcholine + acetate
The residue was finally reconstituted in analar methanol (0.1ml) 
and diluted further, with methanol such that 5yl gave approximately 2
Q.
x 10 cpm. This was stored at -20°C until needed.
3
The product was shown to be 96.6% [ H]ACh when run on thin layer 
chromatography plates (see section 4.3.8 and table 4.2).
3.2.8. The final extraction method and its application to 
superfusion samples
The enzymic extraction procedure was applied to fractions from 
two of the four superfusion chambers, in a parallel study, to
3
determine how much of the released radioactivity was [ HJACh.
To each of the fractions (340yl) NaOH (12yl, 0.02M) was added to 
bring the pH from 7.4 (the pH of the Krebs buffer) to 8.0, the pH 
optimum of ChK (Goldberg & McCaman, 1973). ATP (lOyl; ImM final 
concentration) and ChK (lOyl; 0.06mg/ml final concentration) were 
then added, mixed and incubated at 37°C for 30 min. After incubation 
TPB/acetonitrile (0.3ml; 3mg/ml) was added with mixing, and the 
samples were counted in the presence of 3ml toluene/PPO scintillant 
(25g PP0/51 toluene).
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3.3 RESULTS AND DISCUSSION
3.3.1. Lactate dehydrogenase activity
The homogenate was distributed into three fractions on the 
sucrose gradient (see fig. 3.1) and these were assayed for LDH 
activity (fig. 3.3). The fraction with the greatest occluded LDH 
level was designated as the synaptosome fraction, as high occluded 
LDH indicates greater structural integrity of membrane bound 
structures containing cytoplasm (Johnson & Whittaker, 1963; 
Marchbanks, 1967).
The PA fraction contains mainly myelin fragments (Gray & 
Whittaker, 1962; fig. 4.8A this report) and as expected little of the 
total LDH activity (approximately 30%) was occluded. The high level 
of free LDH in this PA fraction was probably a result of LDH released 
during homogenisation.
As expected the PB fraction being rich in synaptosomes, as seen 
by electron microscopy (Gray & Whittaker, 1962; fig. 4.8B this 
report) had the highest occluded LDH activity which accounted for 
approximately 80% of the total LDH activity in that fraction. It was 
this fraction that was used in future experiments.
The mitochondrial and nuclear pellet, PC (fig. 4.8C), had 
relatively low levels of LDH activity consistent with a small 
synaptosomal content in this fraction. However, only approximately 
50% of the total LDH is occluded suggesting that not all the LDH 
present was purely as a result of synaptosomal contamination.
Although LDH is considered to be a cytoplasmic enzyme, there is a 
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Fig. 3.3. LDH activity in fractions from the sucrose gradient. 
Enzyme activity was assessed by measuring the oxidation of NADH at 
340nm, with pyruvate as substrate, in the presence (total LDH) and 
absence (free LDH) of Triton X-100. Occluded levels were calculated 
as the difference between total and free LDH. Values are the mean ± 
SEM, n=8.
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and ionic strength (Fonnum, 1967) which might account for some of the 
enzyme activity in this fraction.
3.3.2. Characterisation of choline uptake
3
To study [ H]ACh release, the synaptosomes were first pre-loaded
with [ H]Ch. Specific Na+ dependent HAChT in the membrane of
3
cholinergic synaptosomes (Jope, 1979) takes [ H]Ch into the
3
synaptosomes where it is acetylated to [ H]ACh by ChAT, in the 
presence of AcCoA (see section 1.1.2.).
3.3.2.1. The effect of incubation time
3
The time course of [ HJCh uptake (0.8]iM) was studied over a 
period of 0-60 min at 37°C. At time intervals samples (0.1ml) were 
withdrawn, filtered and washed as described in section 3.2.4.1, see 
fig. 3.4.
Non-specific uptake (determined in the presence of lyM HC-3) was 
essentially linear with time and accounted for about 15% of the total
3
[ HJCh taken up. Specific uptake (the difference between total and 
non-specific uptake) approached maximal values at 30 min. Thus 
sufficient labelling of the synaptosomes could be achieved by a 20 
min incubation and this was used in future experiments.
3.3.2.2. The effect of choline concentration
3
The dependence of [ HJCh uptake on Ch concentration was studied 
over the range 0.2-2.0yM. After a 20 min incubation at 37°C samples 
(0.1ml) were taken, filtered and washed as described in section
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Fig. 3.4. The time course of [ H]Ch uptake by sucrose isolated
3
synaptosomes. After the addition of [ HJCh (0.8yM), samples were 
incubated at 37°C and at time intervals (0-60min) lOOyl were taken, 
filtered and washed. Non-specific uptake was determined in the 
presence of HC-3 (lyM). Values for total (•), specific (A) and 
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Fig. 3.5 a). The effect of Ch concentration on [ H]Ch uptake 
by sucrose isolated synaptosomes. Samples were incubated with 
varying [^H]Ch concentrations (0.1-2.0pM) and after 20 min at 37°C 
lOOyl were taken, filtered and washed. Non-specific uptake was 
determined in the presence of HC-3 (lyM). The values for total (•),
specific (A) and non-specific (▼) uptake are the mean ± SEM, n=3.
3
Fig. 3.5 b). A direct linear plot of [ H]Ch uptake against Ch 
concentration. Values are the mean of 3 experiments. Kt (the 
concentration of half maximum transport) and Vmax (maximal transport) 
were derived by determining the mean of the intersections correlating 
to the x-axis (Kt) and y-axis (Vmax).
54
Non-specific uptake was essentially linear with concentration.
Specific uptake approached saturation at a Ch concentration of lyM.
Thus sufficient labelling of the synaptosomes could be achieved by a 
3
[ HJCh concentration of 0.8yM and this concentration was used in 
future experiments.
A direct linear lot (fig. 3.5(b)) gave a Kt value of 0.51yM (the 
concentration for half maximal transport) and a Vmax of 34.5pmol/20 
min/mg protein. This Kt value was within the range reported for 
specific HAChT into hippocampal synaptosomes: 0.43-0.90yM (Sorimachi
& Kataoka, 1974; Atweh et al., 1975; Murrin & Kuhar, 1976; Simon & 
Kuhar, 1976; Simon et al., 1976). These researchers gave Vmax values 
of 16-56.4pmol/4 min/mg protein, from fig. 3.4 the Vmax value of 
26pmol/4min/mg protein is well within this range.
3.3.3. Superfusion
3
3.3.3.1. Derivation of an enzymic separation of [ HJACh 
from [^HJCh
When monitoring drug effects on radiolabelled ACh release from 
tissue pre-loaded with the radioactive precursor Ch, a method that 
will discriminate between the bases is required before changes in 
transmitter levels can be determined.
The procedure described by Wonnacott & Marchbanks (1976) 
involved extracting the choline bases into an organic solvent and the 
subsequent separation of ACh from Ch by thin layer chromatography.
The spots were then removed and measured for radioactivity. The 
enzymic radioassay of Goldberg & McCaman (1973) detailed the 
phosphorylation of Ch to phosphorylcholine which was then separated
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32from the labelled substrate ([ P]ATP) on anion exchange columns.
The method of Marchi et al. (1983) required the samples to be 
lyophilised before Ch was phosphorylated. The addition of TPB in an 
organic solvent would extract ACh into the organic phase, but not 
phosphorylcholine, the radioactivity of which could then be measured 
in the presence of an organic scintillant.
However, these methods are lengthy and not easily applied to the
large number of samples which are obtained from the superfusion
3 3system. Thus an enzymic separation of [ H]ACh from [ H]Ch was 
devised which could be routinely used in the minivials in which the 
superfusion fractions were collected.
3
For these experiments the standards used were: [ H]ACh (5yl;
4 3 a
2.4 x 10 cpm; in methanol) and [ H]Ch (5yl; 2.1 x 10 cpm;
aqueous). Radioactivity of the samples was determined in the
presence of toluene/PPO scintillant (3ml), total radioactivity was
determined in the presence of 3ml Optiphase 'Safe' scintillant.
3.3.3.1.1. The effect of acetonitrile volume
3
When [ H]ACh (in methanol) was mixed directly with toluene/PPO 
scintillant 63% of the total radioactivity was counted (fig. 3.6). 
When the organic solvent, acetonitrile, was added the amount of 
radioactivity detected increased with the volume of solvent. Thus 
the volume of acetonitrile needed to ensure that all the organic 
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Fig. 3.6. The effect of acetonitrile volume on the counting
efficiency of organic phase radioactivity. Values are the mean of 5 
experiments, in quadruplicate, ± SEM and samples were counted in the 
presence of toluene/PPO scintillant. ACh, (A); Ch, (•).
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3
To [ H]ACh (5yl) varying volumes of acetonitrile (0.1-0.5ml) 
were added with mixing before being counted in the toluene/PPO 
scintillant. To ensure that only organic phase radioactivity was
3
counted, [ H]Ch (5yl, aqueous) in Krebs buffer (340yl; the volume of 
superfusion fractions), was either mixed directly with toluene/PPO 
scintillant or had acetonitrile (0.5ml) added before being counted in 
the scintillant. Results were expressed as percent of the total 
radioactivity counted in the organic phase (fig. 3.6).
3
With [ H]ACh maximum counts, 91%> of total, were achieved in the 
presence of 0.5ml acetonitrile. Approximately 95% of the total 
radioactivity was recorded in the presence of 0.3ml acetonitrile and 
so this volume was used in further experiments.
3
Little or none of the aqueous [ H]Ch was registered when mixed 
directly with toluene/PPO scintillant. This rose to approximately 1% 
of total activity when mixed with 0.5ml acetonitrile. This shows 
that acetonitrile alone is not sufficient to extract the aqueous 
radioactivity into the organic phase and that toluene/PPO scintillant 
will only record radioactivity that is present in an organic medium.
3.3.3.1.2. The effect of TPB concentration
TPB complexes with the positively charged quarternary ammonium 
group of ACh and Ch forming a precipitate that is only soluble in 
organic solvents like acetonitrile (Fonnum, 1969).
The effect of TPB concentration, in acetonitrile (0.3ml) on the 
uptake of aqueous radioactivity into the organic phase was studied 
over the range 0.l-10mg/ml, fig. 3.7. To ACh or Ch (5yl in 340yl 
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Fig. 3.7. The effect of TPB concentration on the uptake of 
radioactivity from the aqueous to organic phase. TPB was in 0.3ml 
acetonitrile and samples were counted in toluene/PPO scintillant. 
The values are the mean of 3 experiments, in quadruplicate, ± SEM. 
ACh, (A); Ch, (•).
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concentrations of TPB) was added, mixed and the samples than counted 
in scintillant, see fig. 3.7.
Uptake of aqueous radioactivity into the organic phase increased 
with TPB concentration as more complexed with the choline bases. 
Maximal radioactivity was counted at a TPB concentration of 5mg/ml in 
acetonitrile. However, over 95% of this radioactivity was obtained 
in the presence of 3mg/ml TPB in acetonitrile and this concentration 
was used in further experiments.
This concentration of 3mg TPB/ml acetonitrile was slightly lower 
than that reported of lOmg TPB/ml butyronitrile (Marchi et al., 1983; 
Rowell & Winkler, 1984). The lower value probably reflects the 
smaller superfusate volume used here than by other researchers.
3
3.3.3.1.3. Enzymic phosphorylation of [ H]Ch
A. The effect of choline kinase concentration
The effect of choline kinase (ChK, EC: 2.7.1.32) concentration
on the phosphorylation of Ch, incubated at 37°C for 30 min in the 
presence of 5mM ATP, was studied over the range 0.01-0.06mg enzyme 
protein/ml (Marchi et al., 1983; Rowell & Winkler, 1984), see 
fig. 3.8.
To 5yl samples of [^H]ACh or [^ H]Ch, in 340yl Krebs buffer (pH
8.0) containing 5mM ATP, varying concentrations of ChK (lOyl; 
0.63units/mg) were added to give a final concentration 0.01-0.06mg 
enzyme protein/ml. After mixing, the samples were incubated at 37°C 
for 30 min before 0.3ml TPB/acetonitrile (3mg/ml) was added and then 
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Fig. 3,8. The effect of choline kinase concentration on Ch 
phosphorylation♦ Samples were incubated for 30 min at 37°C with 5mM 
ATP and varying concentrations of choline kinase, then extracted with 
TPB/acetonitrile (0.3ml; 3mg/ml) and counted in toluene/PPO 
scintillant. Values are the mean of 4 experiments, in quadruplicate, 
± SEM. ACh, (A); Ch, (#).
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The phosphoryl group on phosphorylcholine prevents complex
3
formation with TPB and so [ H]Ch radioactivity, present as
phosphorylcholine, remains in the aqueous phase and so is not
3
counted. As ChK concentration increased, so less [ H]Ch was counted 
consistent with increasing phosphorylation of Ch. Maximal 
phosphorylation, 90%, was obtained with 0.06mg/ml ChK, in the 
presence of 5mM ATP, and so this concentration was used in further 
experiments. The acetyl group on ACh prevents its phosphorylation by 
ChK and so it will complex with TPB and be taken into the organic 
phase (fig. 3.8).
B. The effect of ATP concentration
Varying concentrations of ATP (lOyl; 0.2-10mM final 
concentration) were added to samples containing Krebs buffer (340yl; 
pH 8.0), [3H]ACh (5yl) or [3H]Ch (5yl) and ChK (lOyl; O.Olmg/ml). 
These were mixed, incubated at 37°C for 30 min then extracted with 
TPB/acetonitrile (0.3ml; 3mg/ml) and counted.
A suboptimal ChK concentration was used so that the effect of 
ATP concentration on Ch phosphorylation could be seen more clearly. 
Results were expressed as the percent of radioactivity remaining in 
the aqueous phase, fig. 3.9.
Ch phosphorylation increased with ATP concentration up to a 
maximum of ImM ATP, then decreased. ChK requires magnesium, Mg, for 
phosphorylation as it is via a Mg-ATP complex that Ch is 
phosphorylated. When ATP concentrations are greater than those of Mg 
(Mg is 1.2mM in the Krebs buffer) then a less active Mg-(ATP)2 
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Fig. 3.9. The effect of ATP concentration on Ch 
phosphorylation. Samples were incubated at 37°C for 30 min with 
O.Olmg/ml choline kinase and varying ATP concentrations, then 
extracted with TPB/acetonitrile (0.3ml; 3mg/ml) and counted in 
toluene/PPO scintillant. Values are the mean of 4 experiments, in 
quadruplicate, ± SEM. ACh, (A); Ch, (#).
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This Mg-(ATP>2 complex formation could explain why at ATP
concentrations greater than ImM Ch phosphorylation decreases so that
3
more [ H]Ch is taken into the organic phase.
Maximal phosphorylation, 55%, was achieved with ImM ATP and so 
this was used in further experiments. Ch phosphorylation was lower 
than that reported in section 3.3.3.1.3B, fig. 3.8, as the ChK 
concentration was lower in these experiments.
A similar ATP concentration was used by Goldberg & McCaman
(1973). The higher ATP concentration of lOmM used by Marchi et al.
(1983) and Rowell & Winkler (1984) was counterbalanced by the 
addition of lOmM MgC^.
C. The effect of Ch concentration
To ensure that the enzymic conditions, of 30 min incubation at 
37°C with 0.06mg/ml ChK and ImM ATP, were sufficient to phosphorylate 
all the Ch that may be present in the superfusate the Ch 
concentration was increased from 0.165yM (present in 5yl) to 0.465yM 
by the addition of 20yM Ch.
Varying ATP concentrations (lOyl; 0.2-5.0mM final concentration) 
were added to either 0.165iiM or 0.465yM Ch in Krebs buffer (340yl; pH
8.0) with ChK (lOyl; 0.06mg/ml). These were mixed, incubated at 37°C 
for 30 min before TPB/acetonitrile (0.3ml; 3mg/ml) was added and the 
samples were counted for radioactivity, see fig. 3.10.
Phosphorylation increased with ATP concentration and there was 
no significant difference when Ch concentration was increased.
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Fig. 3.10. The effect of ATP concentration on the 
phosphorylation of Ch, at two concentrations. Samples containing 
either 0.165 or 0.465pM Ch were incubated at 37°C for 30 min with 
0.06mg/ml choline kinase and varying ATP concentrations, then 
extracted with TPB/acetonitrile (0.3ml; 3mg/ml) and counted in 
toluene/PPO scintillant. Values are the mean of 2 experiments, in 
triplicate, ± SEM. ACh, (A); 0.165pM Ch, (•); 0.465pM Ch, (y) .
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0.06mg/ml, was obtained with 5nnM ATP (a similar result was seen in 
section 3.3.3.1.3A). However, approximately 90% phosphorylation was 
achieved with ImM ATP (which also gave the maximal results in section 
3.3.3.1.3B, fig. 3.9) and so it was this concentration that was used 
in further experiments.
D. The effect of incubation time
Having defined the optimum concentrations of the assay 
constituents, the effect of incubation time on the enzymic 
phosphorylation of Ch was examined.
To 5yl samples of [ H^JACh or [^ H]Ch, Krebs buffer (340yl; pH 8.0 
with 12yl 0.02M NaOH), ATP (lOyl; ImM) and ChK (lOyl; 0.06mg/ml) were 
added and mixed. These were incubated at 37°C for varying lengths of 
time before TPB/acetonitrile (0.3ml; 3mg/ml) was added and the 
samples counted for radiactivity, see fig. 3.11.
Ch phosphorylation increased with time reaching a maximum of 95% 
after 60 min. Sufficient phosphorylation, 92%, could be achieved 
after a 30 min incubation at 37°C and so this was used in further 
experiments. This incubation time of 30 min at 37°C was within the 
range (15-45 min) reported (Goldberg & McCaman, 1973; Marchi et al., 
1983; Rowell & Winkler, 1984).
3.3.3.1.4. Application of the enzymic extraction to 
superfusion samples
The final enzymic extraction procedure of adding NaOH (12yl; 
0.02M), ATP (lOyl; ImM) and ChK (lOyl; 0.06mg/ml) then incubating at 
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Fig. 3.11. The time course of Ch phosphorylation. Samples 
were incubated at 37°C for varying amounts of time with ImM ATP and 
0.06mg/ml choline kinase, then extracted with TPB/acetonitrile 
(0.3ml; 3mg/ml) and counted in toluene/PPO scintillant. Values are 
the mean ± SEM of 4 experiments, in quadruplicate. ACh, (A); Ch, (•)
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3
four superfusion chambers. After incubation, the [ H]ACh was 
extracted from the aqueous phase by TPB/acetonitrile (0.3ml; 3mg/ml) 
and the samples were counted for radioactivity in the presence of 
toluene/PPO scintillant (3ml), see fig. 3.12b; table 3.1.
Fractions from the other two superfusion chambers were counted 
for radioactivity, directly, in the presence of Optiphase 'Safe' 
scintillant (3ml), see fig. 3.12a, table 3.1.
From fig. 3.12 it can be seen that there is no decrease in basal 
release of radioactivity in the presence of the enzymic extraction
3
suggesting that this is leakage of [ HJACh from the synaptosomes.
Fig. 3.12 and table 3.1 show that there is no significant difference
3
in response to stimulation with 50yM nicotine as the amount of [ H] 
released was equivalent whether in the presence or absence of the 
enzymic extraction. Thus most, if not all the released radioactivity
3
was [ H]ACh and this compares well with the results of Rowell & 
Winkler (1984) who reported that 87% of the nicotine-evoked tritium 
released, from cortical synaptosomes, was associated with ACh.
3.3.3.1.5 Summary of the extraction procedure
The results have shown that the enzymic extraction procedure can 
3 3separate [ H]ACh from [ H]Ch in an aqueous solution. When applied to
samples collected from the superfusion system there was no observed
change in basal or nicotine evoked release of tritium to that seen
when no extraction was applied. This indicates that most, if not
3
all, the released radioactivity was [ HJACh and so the routine use of
3
this procedure was not necessary. It also indicates that [ HJACh was 
removed in the superfusate before it was hydrolysed by any AChE that
68
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Fig. 3.12. Superfusion profiles of ACh release in (a) the 
absence and (b) the presence of the enzymic extraction procedure. 
The synaptosomes were subjected to successive stimulations of 
nicotine (50yM; SI, S2) after a 40 min washout. Samples were 
extracted with TPB/acetonitrile (0.3ml; 3mg/ml) after incubation at 
37°C for 30 min with ImM ATP and 0.06mg/ml choline kinase, 
ji Indicates pulse arriving at the synaptosomes. Numbers in brackets 
are fmol ACh released/mg protein.
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AGONIST ENZYMIC EXTRACTION SI S2
NICOTINE - 59.0 49.9
50yM ± 2.0 ± 3.3
NICOTINE + 56.1 48.2
50yM ± 3.3 ± 2.6
Table 3.1. The effect of the enzymic extraction on the
3
level of [ H]ACh released by nicotine stimulation. Release by
successive stimulations of nicotine (50yM; 40s agonist pulse, 30s air
3




This result correlates veil with the observation that 98% of the
3 3loaded [ H]Ch was converted to [ H]ACh (see section 4.3.8) and so a
3
high [ HJACh content was expected.
3.3.3.2. The nicotinic nature of evoked ACh release
Rowell & Winkler (1984) were one of the first groups to show 
that nicotine evoked ACh release from the CNS, using synaptosomes 
isolated from the cerebral cortex of mice, after pre-loading with
3
[ H]Ch. This nicotine response was blocked by the nicotinic 
antagonist hexamethonium suggesting the effect was via a nAChR.
The nicotinic nature of ACh release from rat hippocampal 
synaptosomes was studied using successive pulses of nicotine (50yM; 
SI, S2 and S3) followed by a K+ pulse (20mM; S4) in the presence and 
absence of the nicotinic antagonist DH|3E (Eccles et al., 1954; 
Krnjevic, 1974; lpM), see fig. 3.13 and table 3.2.
It can be seen in fig. 3.13 and table 3.2 that with successive 
stimulations with nicotine there was a reduction in evoked release 
(S2/S1 *s 84%; S3/S1 = 75%, see table 3.4) which could be due to a 
decrease in synaptosome responsiveness with time.
In the presence of DH(3E there was a marked reduction in nicotine
evoked release (S2/S1 = 44%; S3/S1 = 34%, see table 3.4) which was
equivalent to approximately 50% of the nicotine evoked release of the
control (in the absence of DH0E; p<0.001). As DH|3E blocks the 
3
nicotine-evoked [ HJACh release it suggests that nicotine stimulated 
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Fig. 3.13. Superfusion profiles of nicotine evoked ACh release 
in (a) the absence and (b) the presence of DHgE. Synaptosomes were 
stimulated with nicotine (50yM; SI, S2, S3) and K+ (20mM; S4) after a 
40 min washout. DHf3E (lyM) was introduced 15 min after the SI pulse. 
 ^ Indicates pulse arriving at the synaptosomes. Numbers in brackets 
are fmol ACh released/mg protein.
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SI S2 S3 S4
Nicotine DH$E Nicotine Nicotine K+
50yM lyM 50yM 50yM 20mM
111.7 - 95.8 83.4 179.2
± 8.8 ± 5.7 ± 6.8 ± 8.4
(n=9)
109.9 + 48.5* 37.8* 188.8
± 6.9 ± 5.7 ± 4.8 ± 7.4
(n=4)
Table 3.2. The effect of DH0E on ACh release evoked by
successive stimulations with nicotine and K+. Nicotine (50yM; SI, S2
and S3) and K+ (20mM; S4) stimulated release in the presence and 
absence of DH0E, introduced 15 min after SI,were expressed as fmol 
ACh released/mg protein ± SEM. Significantly different from control 
(no DH|3E), * p<0.001.
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K+ depolarisation as was expected as K+ depolarisation is independent 
of the nAChR.
3.3.3.3. The effect of (+)anatoxin-a on ACh release
(+)Anatoxin-a (ANTX) is an exotoxin isolated from a filamentous, 
freshwater, blue-green algae Anabaena flosaquae (Carmichael et al., 
1975). It has been found to be a potent stereospecific agonist at 
the nicotinic synapses in frog muscle and Torpedo (Swanson et al.,
3
1985). Though it has been used in [ H]nicotine binding studies in 
rat brain (MacAllan et al., 1988) its functional effects in the CNS 
have not been studied.
3.3.3.3.1. The nicotinic nature of (+)anatoxin-a evoked ACh 
release
In order to examine the nicotinic nature of the effect of 
(+)ANTX on ACh release successive pulses of (+)ANTX (lOyM; SI, S2 and 
S3) were administered in the presence and absence of DHgE, as 
described in section 3.2.5, see fig. 3.14 and table 3.3.
As seen with nicotine stimulation (fig. 3.13, table 3.2) there 
was a successive reduction in evoked release when stimulated with 
(+)ANTX (S2/S1 = 90%, S3/S1 = 80%; see table 3.4) and this is 
probably due to a decline in synaptosome responsiveness with time.
In the presence of lyM DHfSE (table 3.3) there was no significant 
decrease in ANTX-evoked ACh release (S2/S1 = 90%; S3/S1 = 77%; see 
table 3.4). However, when the DHpE concentration was increased to 
lOyM there was a reduction in ANTX stimulated ACh release (S2/S1 * 
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Fig. 3.14. A superfusion profile of successive stimulations of 
ANTX on ACh release. ANTX (10yM; SI, S2, S3), K+ (20mM; S4) and 
Krebs buffer (S5) pulses were administered at 30 min intervals after 
a 40 min washout. | Indicates pulse arriving at the synaptosomes. 
Numbers in brackets are fmol ACh released/mg protein.
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SI S2 S3 S4 S5
ANTX DH|3E ANTX ANTX K+ KREBS
10uM yM lOyM lOyM 20mM BUFFER
32.1 - 28.9 25.8 48.8 15.5
± 2.1 ± 0.9 ± 2.2 ± 2.4 ± 1.6
(n=6)
30.8 1 27.7 23.7 50.6 -
± 2.7 ± 0.2 ± 1.1 ± 1.2
(n=2)
31.8 10 19.5* 12.6** 47.5 -
± 2.4 ± 3.1 ± 2.8 ± 3.0
(n=3)
Table 3.3. The effect of DH|3E on ACh released by 
successive stimulations with ANTX and K*. ANTX (lOyM; SI,
S2 and S3) and K+ (20mM; S4) stimulated release in the presence and 
absence of DH|3E, introduced 15 min after SI, were expressed as fmol 
ACh released/mg protein + SEM. Significantly different from control 
(no DH|3E), * p<0.05, ** p<0.02.
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approximately 50% of the evoked: release of the control (no DHpE 
present). Thus lOyM DH0E inhibited lOyM ANTX evoked release by 
approximately 50%. As before DH{5E had no effect on K+ 
depolarisation. These results indicate that ANTX has an excitatory 
effect on ACh release which is blocked by DHgE suggesting it acts via 
a nAChR.
3.3.3.3.2. Problems with the superfusion system highlighted 
by these experiments
A. Temperature fluctuations
ACh release evoked by K+ depolarisation was greater in table 3.2 
than table 3.3 suggesting a problem with the system. The lower 
response could be due to reduced experimental temperatures of the 
laboratory (see section 3.3.3.4.4.) where decreases in external 
temperatures correlated with a decline in synaptosomal 
responsiveness.
Indeed, a decrease in the laboratory temperature could explain 
why ANTX stimulated ACh release (table 3.3) was lower than that 
elicited by nicotine (table 3.2). It was expected that ANTX effects 
on ACh release would be equal or greater than those of nicotine, as
3
[ HJnicotine binding studies, to rat P2 membranes, has shown ANTX (Ki 
= 3.4 x 10 ~^M) to be approximately 50 fold more potent than 
nicotine (Ki = 1.5 x 10 ”®M), MacAllan et al. (1988).
When the response to agonist is quantified (Sn/Sl; table 3.4) 
there appears to be a similar decrease with successive stimulations 
of agonist (in the absence of DH0E) with both nicotine and ANTX. The 











- 84% 75% 160%
NICOTINE
50yM
1 44% 34% 172%
ANTX
lOyM
- 90% 80% 152%
ANTX
lOyM
1 90% 77% 164%
ANTX
lOyM
10 61% 40% 149%
Table 3.4. Comparison of successive stimulations of 
nicotine, ANTX and K+. Nicotine (50yM; SI, S2 and S3) or ANTX (lOyM; 
SI, S2 and S3) and K+ (20mM; S4) stimulation in the presence and 
absence of DH£E, introduced 15 min after SI, expressed as a percent 
of the SI response.
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identical throughout all the experiments (160% ± 4.1).
Nicotine stimulation was blocked, by 50%, in the presence of lyM 
DH|3E whereas 10yM DH0E was required to show a similar inhibition of 
ANTX evoked release. This 10 fold greater requirement for DH0E 
suggests that ANTX could be a more potent agonist than nicotine as it 
needs higher concentrations of the competitive antagonist to block 
its effects. However, although ANTX appears to be a more potent 
agonist than nicotine (when quantitatively comparing antagonist 
effects) parallel experiments where agonist is administered under the 
same temperature conditions need to be carried out before functional 
potency can be determined.
B. Air bubble effect
When a pulse of Krebs buffer was given as a control there was, 
surprisingly, a significant amount of tritium released (S5: fig
3.14; table 3.3), which represented almost 50% of agonist evoked 
release. This effect was probably due to the air bubble, which 
separates the pulse from the washing buffer, causing some kind of
3
mechanical effect on the synaptosomes provoking [ H]ACh release.
This was probably as a result of re-introduction of buffer after the 
air bubble has passed (see diagram in section 3.2.5) and highlights 
another limitation of the superfusion protocol, which was examined 
further in section 3.3.3.4.1.
The influence of the air bubble artefact was illustrated in the 
determination of the concentration dependence of ANTX on ACh release.
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This was studied by varying the ANTX concentration (l-50yM) in 
the S2 agonist pulse, see fig. 3.15.
Evoked release reached maximal at a concentration of 20yM. When 
the effect of the air bubble was taken into account, a curve of 
similar shape was obtained but lyM ANTX had little or no effect above 
this non-specific release. A direct linear plot of ACh release 
(after the air bubble effect had been deducted) against ANTX 
concentration (not shown) gave an EC50 (concentration to give half 
maximal effect) of 7.5yM and a Vmax (maximum effect) of 23.9 ± 3 fmol 
ACh released/40s/mg protein.
3.3.3.4. Modifications made to the superfusion protocol
The experiments carried out so far have highlighted some 
limitations to the superfusion protocol used to study ACh release.
One such problem was that the air bubble, which separates the agonist 
pulse from the washing buffer, appears to provoke tritium release 
from the synaptosomes. Another was that the responsiveness of the 
synaptosomes was temperature sensitive. Both of these effects were 
examined as outlined below.
3.3.3.4.1. The air bubble effect
A. Size dependence
As a 30s air bubble provoked 50% of the agonist evoked release 
(see fig. 3.14, table 3.3), was the effect dependent on the size of 
the air bubble? This was investigated by administering 40s pulses of 
nicotine (50yM) or Krebs buffer, separated from the washing buffer by 
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Fig. 3.15, The effect of ANTX concentration on ACh 
release. The concentration of ANTX in the S2 pulse was varied, 
and the values are the mean ± SEM, n = 2. (#) Indicates evoked
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Fig. 3.16. A superfusion profile shoving the effect of 
increasing air bubble size on nicotine evoked ACh release. Air 
bubble size was increased with successive stimulations of nicotine 
(50yM; SI: 10s; S2: 20s; S3: 30s). | Indicates pulse arriving at




From fig. 3.16 and table 3.5 it can be seen that there is an 
increase in tritium release with increasing air bubble size. When 
the amount of release (fmol/mg protein) was plotted against air 
bubble size (fig. 3.17) effect due to air bubble was linear with 
respect to size. When the release provoked by air bubble was 
deducted from that evoked by nicotine the response was constant 
indicating that the increase in ACh release, with subsequent 
stimulations of nicotine (50pM), was due to an increase in air bubble 
size.
When the air bubble was 5s duration, not shown, the pulse was 
not retained as a discrete volume as the air bubble became lost in 
the tubing. Thus an air bubble of 10s duration was used in further 
experiments as it had the smallest effect on tritium release but was 
still large enough to retain a discrete pulse throughout the tubing 
of the superfusion system.
B. The need for an air bubble
As an air bubble provokes tritium release is it necessary to 
have an air bubble when introducing an agonist?
To investigate this, a 40s pulse of a dye was introduced into 
the superfusion tubing in the presence and absence of a 10s air 
bubble. Benzoquinonium chloride was used as it is dark pink/red in 
colour and so its passage could be followed through the tubing. The 
length of the pulse was measured when it was first introduced and 
again just prior to reaching the filter support in the superfusion 
chamber (a distance of 143cm). The change in pulse length was noted
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Fig. 3.17. The effect of air bubble size on tritium release. 
Air bubble size was increased with successive stimulations with 50yM 









NICOTINE 48.3 63.9 75.1
50yM ± 0.3 ± 4.2 ± 3.6
KREBS 22.8 30.5 41.5
BUFFER ± 0.7 ± 2.2 ± 3.7
Table 3.5. The effect of air bubble size on release of tritium. Air
bubble size was increased with successive pulses of nicotine (50yM) 




As shown in table 3.6 there was no increase in the pulse length 
when it was separated from the washing buffer by an air bubble. 
However, without an air bubble there was considerable diffusion of 
the pulse resulting in a six fold increase of pulse length from start 
to finish.
Thus an air bubble was required to retain a discrete pulse of 
known concentration and prevent agonist diffusion which would prolong 
synaptosome stimulation.
C. Use of an injection pump
If the agonist pulse, without air bubble, was introduced closer 
to the synaptosomes there would be less distance for diffusion. A 
three way injection pump, attached to the top of the superfusion 
chamber (see fig. 3.2), was used to investigate this as agonist, 
present in a known concentration and volume in the pump, could be 
administered by diverting the washing buffer through the pump and on 
to the synaptosomes.
A superfusion profile showing the effect of nicotine (lOOyl; 
50yM) stimulation on ACh release, via a three way injection pump, was 
shown in fig. 3.18. It can be seen that there are no clear peaks of 
evoked release (n = 5). The baseline was quite erratic which could 
be due to diffusion of the agonist, even in the short length of 
tubing from the top of the chamber to the synaptosomes resulting in 
prolonged agonist stimulation of unknown concentration.
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TUBE AIR BUBBLE PULSE SIZE AT PULSE SIZE AT
10s START (mm) FINISH (mm)
A + 28.5 28.5
B - 61.0 383.5
Table 3.6. The change in pulse length through the





























• • -  . • • • ♦ „  
••• •
i i i i i i i i i rn i
18 22 26 30 34 38 42 46 50 54 58 62 66
Fraction number
Fig. 3.18. A superfusion profile of ACh release when nicotine 
vas administered via a three way injection pump. Nicotine (50yM; 
lOOyl) was given at 30 min intervals after a 40 min washout period.
 ^ Indicates pulse arriving at the synaptosomes.
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Thus from these results it was clear that an air bubble was 
required to retain a discrete pulse of agonist stimulation of known 
concentration and duration. As a 10s air bubble was the minimum size 
for retaining the agonist pulse, the response to nicotine was studied 
to determined if it could be increased by manipulating the volume of 
agonist administered.
3.3.3.4.2. The effect of agonist pulse size
It has been reported that nicotine could desensitize the 
receptor which would reduce the response to nicotine (Egan & North, 
1986; Clarke et al., 1985). Thus a pulse size of 40s duration with 
50yM nicotine could be long enough to cause desensitisation. This 
was studied by varying the pulse size (20s-40s duration) of a known 
concentration of either nicotine (50yM), DMPP (the nicotinic agonist
l,l,dimethyl-4-phenylpiperazinium, 50yM) or K+ (20mM) separated from 
the washing buffer by a 10s air bubble, see fig. 3.19 and table 3.7.
The release in response to buffer was not dependent on the size 
of the pulse indicating that Krebs buffer alone does not provoke 
tritium release but the increase above basal, was due to the air 
bubble.
When DMPP or K+ was given as a pulse there was a trend towards 
an increase in ACh evoked release, though not significant, with 
increasing pulse size i.e. the more agonist present the greater the 
evoked release. However, the response to nicotine decreased with 
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Fig. 3.19. A superfusion profile shoving the effect of 
increasing pulse size on evoked ACh release. The pulse size was 
increased with successive stimulations with DMPP (50yM; SI: 20s; S2:
30s; S3: 40s). | Indicates pulse arriving at the synaptosomes.









KREBS 26.5 24.2 21.2
BUFFER ± 1.3 ± 2.0 ± 2.6
(n=3)
NICOTINE 85.7 65.0 50.8
50yM ± 4.4 ± 3.8 ± 2.0
(n«4)
DMPP 92.8 116.7 139.4
50yM ± 2.6 ± 4.1 ± 3.4
(n=2)
K+ 184.7 200.9 219.4
20mM ± 1.4 ± 2.9 ± 4.6
(n=3)
Table 3.7. The effect of varying pulse size on ACh release. Pulse
size was increased with successive stimulation with Krebs buffer, 
nicotine (50yM), DMPP(50yM) or K+(20mM). Values are fmol ACh 
released/mg protein ± SEM.
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The maximum response to nicotine (50yM) was achieved by a 20s 
agonist pulse separated from the washing buffer by a 10s air bubble 
and it was these conditions that were used in further experiments.
3.3.3.4.3. The effect of nicotine concentration
Nicotine concentration may also have an effect on 
desensitisation. To investigate this, the effect of successive 
stimulations of nicotine (10yM or 50uM) was studied using a 20s 
agonist pulse and a 10s air bubble, see table 3.8.
From table 3.8, 50yM nicotine evoked approximately 30% less ACh 
than 10yM nicotine. A similar reduction in ACh release, with 
increasing agonist concentration, was reported by Lapchak et al. 
(1989) when using the nicotinic agonist methylcarbamylcholine. This 
suggests that the higher nicotine concentration (50yM) may be causing 
some receptor desensitisation thus reducing the level of ACh 
released.
The effect of the air bubble was equivalent in the two 
experiments. However, the response to air bubble amounted to 
approximately 25% of that evoked by lOyM nicotine (S3/S1) as opposed 
to 35% of that evoked by 50yM nicotine (S3/S1). This reduction in 
the air bubble effect probably reflects the increase in response to 
the lower nicotine concentration.
The conditions of a 20s pulse of lOyM nicotine, separated from 
the washing buffer by a 10s air bubble, was observed as giving the 








10 118.2 92.2 28.5
± 6.2 ± 4.8 ± 3.5
50 81.8* 69.8** 28.5
± 4.0 ± 3.0 ± 3.9
Table 3.8. The effect of nicotine concentration on
ACh release. Values are fmol ACh released/mg protein ± SEM, n=6. 
Significantly different from the response to lOyM nicotine,
* p<0.001, ** p<0.005.
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3.3.3.4.4. The effect of temperature
As discussed in section 3.3.3.3.2.A the response to agonist 
could be temperature sensitive. This was illustrated in fig. 3.20 
where superfusion profiles of ANTX evoked ACh release were compared 
when the laboratory temperature was either 18°C or 25°C.
At 18°C (fig. 3.20a) there was no significant response to 
agonist above baseline whereas there were discrete peaks of evoked 
release at 25°C (fig. 3.20b). Such variation in agonist response due 
to changes in laboratory temperature makes the comparison of 
different preparations difficult. Thus a constant temperature 
cabinet (fig. 3.21) was constructed to eliminate this problem.
The temperature cabinet was a perspex box enclosing the entire 
superfusion apparatus with sliding doors for access. Inside the 
cabinet was a fan heater attached to a cut-off thermometer, to 
maintain a constant temperature and a conductor fan to circulate the 
air, see fig. 3.21. Although the optimum temperature would have been 
37°C this was difficult to maintain in the air heated cabinet so a 
constant temperature of 32°C was used in further experiments.
3.4. Summary
These experiments have shown that nicotine evoked tritium 
release from hippocampal synaptosomes, after optimal labelling with
3
[ H]Ch, could be monitored in a superfusion system. An enzymic 
extraction method was developed which showed that most if not all the 
tritium released was ACh. Inhibition of nicotine-evoked ACh release 
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Fig. 3.20. Superfusion profiles of ANTX evoked ACh 
release at (a) 18°C and (b) 25°C. Synaptosomes were subjected to 
successive stimulations with ANTX (lOyM; SI, S2, S3) after a 40 
min washout period.  ^Indicates pulse arriving at the synaptosomes 
Numbers in brackets are fmol ACh released/mg protein.
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]
Fig. 3.21. A schematic diagram of the superfusion constant 
temperature cabinet. CF: conductor fan; CT: cut off thermometer;
FC: fraction collector; FH: fan heater; P: pump; SC: superfusion
chamber; SD: sliding door; WB: washing buffer.
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However, some limitations of the superfusion protocol, of Rapier 
et al. (1988), for studying nicotine-evoked ACh release have been 
highlighted. To reduce day to day fluctuations in synaptosomal 
responsiveness, due to changes in laboratory temperatures, subsequent 
superfusion experiments were carried out in a constant temperature 
cabinet (32°C), fig. 3.21.
The response to nicotine was maximised by reducing the 
concentration and pulse size of agonist given, thus decreasing 
receptor desensitisation. Therefore 10uM nicotine in a 20s pulse was 
routinely administered in further experiments.
Results have also shown that air bubble provoked tritium release 
in a size dependent manner. The requirement for an air bubble has 
been shown to be necessary to retain a discrete agonist pulse of 
known concentration. The effect of air bubble was minimal at 10s 
duration and so was used in further experiments.
The adapted superfusion protocol was that a 20s agonist pulse 
was administered, separated from the washing buffer by a 10s air 
bubble. All superfusions were carried out in a 32°C constant 
temperature cabinet. The effect due to the air bubble was 
continually monitored, by giving a pulse of buffer, and this value 
was routinely deducted from the agonist evoked release to determine 
the response due to the drug.
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During the course of these experiments Dunkley et al. (1987) 
reported that subcellular fractionation of a SI supernatant, on a 
discontinuous Percoll gradient, produced an enrichment of 
synaptosomes for the study of noradrenaline release from the cortex. 
This protocol was adopted to determine whether subcellular 
fractionation of the hippocampus on Percoll gradients, would produce 
a purer synaptosomal preparation to study ACh release. This was 
undertaken as the response of sucrose isolated synaptosomes to 
nicotine evoked ACh release was small and differences between agonist 
effects were difficult to determine. Thus it was thought that an 
enriched population of cholinergic synaptosomes would enable the 
nicotinic modulation of ACh release to be better characterised.
4.2. METHODS
4.2.1. Synaptosome isolation on a discontinuous Percoll 
gradient
The subcellular fractionation of hippocampal SI supernatant on 
discontinuous Percoll gradients was as described by Dunkley et al. 
(1987, 1988).
Male Wistar rats (200-250g) were killed by cervical dislocation, 
the brain was removed and the hippocampus dissected out. The 
hippocampi from six rats (600-650mg wet weight) were homogenised (10% 
w/v in 0.32M sucrose, pH 7.4) in a pre-cooled glass-teflon 
homogeniser (clearance 0.31mm) by 2 x 6 up and down strokes at 
200rpm. The homogenate was then centrifuged at l,000g for 10 min at 
4°C in a MSG 18 centrifuge using a 16 x 15ml fixed
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angle rotor. The supernatant, SI, made up to 8ml with 0.32M sucrose, 
was layered on to four Percoll gradients using a peristaltic pump set 
up with a large bore needle (19G x 1.5 inch; running speed lml/min).
To make the gradients, Percoll was first filtered using a 
Millipore AP15 pre-filter, to remove aggregates which otherwise 
sediment during washing. Then the gradients, comprising 2ml of 23%, 
15%, 10% and 3% Percoll (v/v in 0.32M sucrose, pH 7.4) were layered 
using a peristaltic pump set up with a fine bore needle (25G x 15/16 
inch; running speed lml/min). The gradients were stored at 4°C for 
up to 24 hr before use.
After layering the SI supernatant, the gradients were 
centrifuged at 32,000g for 5 min at 4°C in a MSE 18 centrifuge using 
a 16 x 15ml fixed angle rotor. Centrifugation time was important 
because this non-equilibrium procedure separates subcellular 
particles on the basis of size as well as density, in contrast to 
conventional isopycnic gradients, and so did not include acceleration 
and deceleration. Centrifugation times of less than 3 min results in 
incomplete movement of subcellular particles. Whereas prolonged 
centrifugation beyond 5 min disrupts normal fractionation of the 
organelles, as Percoll particles are not of uniform size, and so 
gradients would form within each Percoll step.
After centrifugation five major subcellular fractions were 
obtained (interfacial fractions F1-F4 and a pellet F5, see fig. 4.1).
Each fraction F1-F5 was taken, using a pasteur pipette, and 
washed twice with Krebs buffer (10ml) by centrifugation at 15,000g 
for 15 min at 4°C in a MSE 18 centrifuge using a 16 x 15ml fixed
100












Fig. 4.1. A schematic diagram of the subcellular distribution 
of the hippocampal SI supernatent on a discontinuous Percoll 
gradient. The gradient after centrifugation at 32,500g for 5 min at 
4°C in a MSE 18 centrifuge using a 16x15ml fixed angle rotor.
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angle rotor. The fractions were finally resuspended in Krebs buffer 
(F1-F4, 1.5ml; F5, 0.7ml) using a pasteur pipette.
4.2.2. Protein determination
4.2.2.1. Standard Lowry
The protein content of each fraction (SI, F1-F5) was determined 
using the method of Lowry et al.,(1951) as described in section
3.2.3.
4.2.2.2. Modified Lowry for samples containing detergent
Protein concentrations of samples containing detergent were 
determined using the method of Markwell et al.,(1978). A standard 
curve was constructed using a freshly prepared solution of BSA in 
Triton X-100 buffer (for composition see section 4.2.5.) over the 
concentration range of 20-100yg/ml.
To 0.1ml of BSA standard or sample (diluted in Triton X-100 
buffer: SI, 1/10, 1/20; F1-F5, 1/4, 1/8) 1ml of reaction mixture was
added, mixed and incubated for 10 min at room temperature. The 
reaction mixture consisted of 100 vol of solution A (2% Na2COy  0.4% 
NaOH, 0.16% sodium tartrate and 1% sodium dodecyl sulphate) mixed 
with 1 vol solution B (4% CuSO^S^O). After incubation, 0.1ml 
Folin-Ciocalteau's reagent, diluted 1:1 with distilled water, was 
added to each sample with mixing and the colour allowed to develop 
for 45 min at room temperature. Blanks contained 0.1ml of Triton 
X-100 buffer in place of protein. The absorbance was read at 750nm 
in a Pye Unicam SP8-100 spectrophotometer.
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4.2.3. Lactate dehydrogenase assay
LDH activity of each fraction (SI, F1-F5) was determined using 
the method of Johnson (1960) as modified by Marchbanks (1967); this 
was outlined in section 3.2.2.
4.2.4. Acetylcholinesterase assay
When ACh is released from the presynaptic nerve terminal it is 
hydrolysed by AChE. Thus AChE activity gives an indication of the 
possible cholinergic nature of neurones but because of its ubiquitous 
distribution it is a non specific plasma membrane marker.
The levels of AChE can be assayed by allowing the enzyme to 
hydrolyse thiocholine esters, following the protocol of Ellman et al. 
(1961). The thiol produced exchanges with 5,5'-dithiobis (2 
nitrobenzoate) (DTNB) in situ, producing 5-mercapto-2-nitrobenzoate. 
This is yellow in colour and so the rate of reaction can be measured 
by following the change in optical density at 412nm with time.
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The reaction is as follows:
AChE
CH2COSCH2CH2N+(CH3)3 + H20 ■> CH2C00H + HSCH2CH2N+(CH3)3
acetylthiocholine acetate thiocholine
CO CO
n o2 + hsch2ch2n +(c h3)3
DTNB thiocholine
CO
02N ^  ^ S H  + 02N ^ SS(CH2)2N+(CH3)3
5mercapto-2-nitrobenzoate
yellow colour
Samples (0.1ml, SI; 0.5ml, F1-F5) of the fractions from the 
Percoll gradient were added to 0.1M phosphate buffer (2.7ml; 0.1M 
KH2P0^: 0.1M Na2HP0^, pH 8.0) and incubated at 37°C for 30 min.
Then the samples were cooled to room temperature before being placed 
in a cuvette (3ml). To these 0.1ml DTNB solution (0.01M DTNB, 15mg 
NaHC03 in 0.1M phosphate buffer, pH 7.4) was added followed by 0.1ml 
of 0.015M acetylthiocholine iodide (in 0.1M phosphate buffer, pH 
8.0). This was stirred rapidly and the change in absorbance at 412nm 
was recorded for a few minutes.
The results were expressed as pmoles of acetylthiocholine 
hydrolysed/min/mg protein:
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vol in cuvette 1
x ------------  x - x 10~3
vol in sample p
A = change in absorbance/min
I 1
E = molar absorption coefficient (1.34 x 10 Mem- )
1 = length of light path (1cm) 
p = protein concentration (mg/ml)
ACh hydrolysis, by AChE, is undesirable when studying the
effects of drugs on ACh release, especially when using more complex
models like the hippocampal slice (see section 6.3). To estimate the
concentration of the AChE inhibitor, BW284C51, needed to block AChE
activity the AChE assay, described above, was repeated using the SI
supernatant (0.1ml) in the presence of varying concentrations of 
-4 -10
BW284C51 (10 - 10 M in 0.1M phosphate buffer, pH 8.0). The SI
fraction was used as it gives a better representation of the AChE 
activity in the hippocampal slice than any one of the fractions from 
the Percoll gradient.
4.2.5. Choline acetyltransferase assay
The cholinergic nature of the fractions from the Percoll 
gradient was further investigated by assaying for the cholinergic 
marker ChAT.
The protocol used was based on the liquid cation exchange 
procedure described by Fonnum (1975). The washed fractions from the 
gradient were resuspended in Triton X-100 buffer (comprising: 0.05M
phosphate (KH2P04, Na2HP04), 0.2M NaCl, ImM EDTA and 0.5% Triton 





(see section 4.2.2.2., modified Lowry for samples containing 
detergent). For each fraction the following reaction mixtures were 
set up in duplicate:
Total activity = 20yl assay buffer + lOyl sample
Assay blank = 20yl assay buffer + lOyl sample + 20yl formic acid
The assay buffer was freshly prepared on the day of use and 
comprised: 12.5mM choline chloride, O.lmM neostigmine bromide, 0.2mM
3
[ HJAcCoA (specific activity lOyCi/ymol) and 5mg/ml BSA in Triton 
X-100 buffer.
The reaction mixtures were incubated at 37°C for 10 min before 
the reaction was stopped by the addition of 20yl formic acid. To 
each sample 0.3ml tetraphenylboron(TPB)/heptan2one (15mg/ml) was 
added, shaken vigorously and centrifuged in a microfuge for 3 min at 
high speed (12,000g). A sample (150yl) of the upper organic phase 
was taken and added to 5ml of scintillant. Vials were cooled at 4°C 
overnight, to reduce chemiluminescence, before being counted.
The standards used were:
150yl TPB/heptan2one
150yl TPB/heptan2one + lOyl assay buffer
This latter standard was used to determine the counting 
efficiency.
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Specific ChAT activity (the difference between total activity
3
and assay blank) was expressed as ymoles [ H]ACh produced/min/mg 
protein:
specific ChAT activity x 2 x 1 x 30
-------------------------------  x mg/ml
c.e. x 2.2 x 10  ^x 10 x 10
where 2 * dilution factor, counted 150yl from 300yl 
1 = assumed 100% extraction 
30 = lOyl sample in 300yl extraction mixture 
c.e. = counting efficiency 
2.2x10  ^= dpm/yCi
3
10 = specific activity of [ HJAcCoA (yCi/ymole)
10 = incubation time (min) 
mg/ml = protein concentration
4.2.6. Bromoacetylcholine synthesis
In the presence of AcCoA the mitochondrial enzyme carnitine 
acetyltransferase (EC: 2.3.1.7) will acetylate carnitine to
acetylcarnitine. When carnitine levels are low carnitine
acetyltransferase will use Ch as an alternative substrate producing
ACh (White & Wu, 1973; Tucek, 1985). To ensure that the
radioactivity measured in the above assay was ACh produced by ChAT 
and not by carnitine acetyltransferase an inhibitor was synthesised. 
This inhibitor was bromoacetylcholine which acts as a competitive 
substrate for ChAT (Morris & Grewaal, 1971; Kasa & Morris, 1972; 
Roskoski et al., 1974). Thus any radioactivity measured in the 
presence of bromoacetylcholine would be due to carnitine 
acetyltransferase activity.
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The synthesis of bromoacetylcholine follows that described by 
Chiou & Sastry (1968) and produced the perchlorate salt.
To 4.60g choline bromide (0.025moles) placed in an Erlenmeyer 
flask, cooled in ice water, 6.06g bromoacetylbromide (0.03moles) was 
added with stirring. The reaction product (a viscous mass) was 
dissolved in 3.75ml ice cold absolute ethanol before 2.81ml of 70% 
perchloric acid was added. A white precipitate separated which was 
filtered and recrystallised from acetone-ethylacetate.
To determine non-specific acetyltransferase activity the 
following reaction mixture was set up in duplicate:
non-specific acetyltransferase = 20pl assay buffer + lOyl sample 
activity + lOyl bromoacetylcholine (O.lmM)
After a 10 min incubation at 37°C the reaction was stopped by
the addition of 20yl formic acid. ACh was extracted into
TPB/heptan2one, centrifuged and then counted in the presence of 
scintillant, as described above.
4.2.7. Choline uptake by fractions from the Percoll 
gradient
3
The parameters used for [ H]Ch uptake by the fractions, from the 
Percoll gradient, were those determined for uptake by the sucrose 
gradient synaptosome fraction (see section 3.2.4.2.).
The fractions were pre-equilibrated at 37°C for 10 min before
3
[ H]Ch (0.8yM final concentration) was added and the samples
incubated for a further 20 min at 37°C. A sample (100yl) was then
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taken, filtered and washed with Krebs buffer (5ml) and counted in the 
presence of 5ml scintillant. Non-specific uptake was determined in 
the presence of HC-3 (lyM). Results were expressed as pmoles choline 
taken up/mg protein.
4.2.8. Characterisation of choline uptake by fraction F4
3
The parameters used for [ H]Ch uptake, above, were optimal for 
choline uptake by sucrose isolated synaptosomes. The conditions for 
uptake were examined to determine if these parameters were also
3
optimal for [ H]Ch uptake by fraction F4 from the Percoll gradient.
4.2.8.1. The effect of incubation time
At time intervals (0-60 min) samples (lOOyl) were taken, 
filtered, washed and counted in 5ml scintillant, as described in 
section 3.2.4.1. Non specific uptake was determined at 4°C.
4.2.8.2. The effect of choline concentration
The effect of varying choline concentration (0.1-2.0pM) on 
choline uptake was determined as described in section 3.2.4.2. 
Non-specfic uptake was determined at 4°C.
3 3
The final [ H]Ch loading conditions used were 0.8yM [ H]Ch 
incubated for 20 min at 37°C after a 10 min pre-equilibration period.
3
4.2.9. Acetylation of [ H]Ch by fraction F4 synaptosomes
3
Having established the optimum [ H]Ch loading conditions by 
fraction F4 synaptosomes, above, the percent acetylation of this 
accumulated [ H]Ch was determined to give an indication of the 
proportions of radioactivity associated with Ch and ACh in the
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synaptosome preparation, used in the superfusion system. ACh was 
separated from Ch by thin layer chromatography after the choline 
bases had been extracted from the synaptosomes.
4.2.9.1. Extraction of ACh and Ch from synaptosomes
The method used was based on that described by Wonnacott &
3
Marchbanks (1976). Fraction F4 (1ml) was loaded with [ H]Ch 
(0.8yM), as described above in section 4.2.8.2., and after the 20 min
3
incubation excess [ H]Ch was removed by washing in Krebs buffer (1ml) 
and centrifugation in a microfuge at low speed (3,000g, 7 min). The 
pellet was resuspended in Krebs buffer (1ml) and samples (0.2ml) 
placed into four eppendorf tubes together with 3M perchloric acid 
(0.1ml). These were mixed and left at 4°C for 15 min.
3
A control sample (fraction F2) containing [ H]ACh, synthesised 
as described in section 3.2.7., was set up to determine the percent 
hydrolysis of ACh that may occur during the extraction procedure. 
Fraction F2 (1ml) was incubated at 37°C for 30 min, washed with an 
equal vol of Krebs buffer with centrifugation in a microfuge, as 
above. The pellet was resuspended in Krebs buffer (1ml) and 0.2ml 
samples were placed into four eppendorf tubes together with 3M
3
perchloric acid (0.1ml). These were mixed before [ H]ACh (20yl; 1.0
5
x 10 cpm) was added, mixed and left at 4°C for 15 min.
The following steps were applied to each of the test and control 
samples, at each step a sample (20pl) was taken to determine the 
amount of radioactivity present. All the solutions and samples were 
kept on ice, except during centrifugation, to keep ACh hydrolysis to 
a minimum.
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After 15 min at 4°C the protein was sedimented by centrifugation 
in a microfuge, as before. A sample of the supernatant (0.25ml; step 
1) was taken and mixed with ^ 2^ 0  ^(0.1ml; 1M) before 1ml of 
TPB/heptan2one (20mg/ml) was added. This was mixed for 15s before 
the two phases were separated by centrifugation, as above. TPB 
complexes with the choline bases and takes them into the organic 
solvent, heptan2one (see section 3.3.3.2.; Fonnum, 1969). A sample 
(0.8ml) of the organic phase (step 2) was mixed with 0.4M HC1 (0.8ml) 
and the two phases were separated by centrifugation, as above.
Strong acids are used to replace the choline esters by H+ ions in the 
complex with TPB (Fonnum, 1969) so the bases pass into the aqueous 
phase. The upper organic phase was discarded and samples (0.65ml) of 
the aqueous phase (step 3) were frozen in liquid nitrogen before 
being freeze dried overnight.
4.2.9.2. Separation of the choline bases by thin layer 
chromatography
The separation of Ch and ACh by thin layer chromatography uses 
the method of Hemsworth & Morris (1964) as described by Marchbanks & 
Israel (1971).
The freeze dried samples were dissolved in a carrier solution
(25ul; analar methanol containing lOmM Ch and lOmM ACh) and samples
(10pl) were spotted onto thin layer chromatography plates coated with
cellulose (MN300HR cellulose, 0.25mm thick). Samples of [^H]Ch or 
3
[ H]ACh (both 1:1 with the carrier solution) were also spotted on the
3
plates. The [ H]Ch spot would give an indication of the percent
crossover of radioactivity from Ch to ACh on the plates and the 
3
[ H]ACh spot would give the percent acetylation of the synthesised
Ill
3
[ H]ACh standard which was used in the control samples.
The plates were then eluted with butanlol: 95% ethanol: glacial 
acetic acid: distilled water (8:2:1:3 by vol; Augustinsson & Grahn, 
1953). Once the solvent front had ascended at least 12cm the solvent 
front was marked and the plates allowed to dry at room temperature. 
The choline bases were identified by spraying with iodoplatinate 
reagent (0.15% potassium chloroplatinate, 3% potassium iodide in 
HC1). ACh appeared as a purple spot with a Rf value of 5.6 and Ch 
appeared as a blue spot with a Rf value of 4.6 (see fig. 4.11). Rf 
values were determined by the distance the base had moved relative to 
the solvent front.
The spots were scraped off the plates into minivials, 
decolourised with 5% (w/v) Na2S0  ^in ethanol (20yl) and 0.1M 
ethanolic ammonia solution (0.6ml). Radioactivity was counted in the 
presence of 3ml scintillant.
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CALCULATIONS
The percent hydrolysis of ACh in the control samples was 
determined:
ACh
1 _   x 100
ACh + Ch
where ACh = radioactivity in the ACh spot
Ch = radioactivity in the Ch spot
The percent acetylation of the test samples was determined:
ACh 1
  x --------------------  x 100
ACh + Ch 1 - fractional hydrolysis
where ACh = radioactivity in the ACh spot
Ch = radioactivity in the Ch spot
4.2.10. Superfusion of synaptosomes isolated on sucrose and 
Percoll gradients.
The effect of nicotine on ACh release from either the sucrose 
gradient synaptosome fraction or fraction F4 from the Percoll 
gradient was studied, in parallel, by superfusion (as described in 
section 3.2.5.).
3
The [ H]Ch loaded synaptosomes (0.8yM, final concentration, 20 
min at 37°C) were washed with an equal vol of Krebs buffer, to remove 
excess label. The pellets were gently resuspended in Krebs buffer 
(approximately lmg/ml) and samples (150yl) were placed in the
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superfusion chamber (see fig. 3.2). After a 40 min washout period, 
the synaptosomes were stimulated at 30 min intervals with a 20s pulse 
of drug (SI & S2, 10yM nicotine; S3 Krebs buffer; S4, 20mM K+). The 
agonist pulse was separated from the washing buffer by a 10s air 
bubble. The evoked release was quantified by summing the 
radioactivity in the fractions contributing to a peak of release, 
after subtraction of basal release, and expressed as fmoles ACh 
released/mg protein.
4.2.11. Electron microscopy
Each fraction from the Percoll gradient (SI, F1-F5, see 
fig. 4.1) and the sucrose gradient (PA, PB and PC, see fig. 3.1) was 
examined by electron microscopy.
Samples (0.2ml) of each fraction from both gradients (see 
section 3.2.1. for sucrose gradient; section 4.2.1. for Percoll 
gradient) were washed three times with 0.1M phosphate buffer (1ml; 
0.5M Na2HP0 ,^ 0.5M KI^PO^, pH 7.4) by centrifugation for 7 min in a 
bench microfuge, at low speed (3,000g). This removes bicarbonate 
from the samples which would otherwise cause granular precipitates 
with the osmium fix (see below). The proteins in the samples were 
then fixed in 1ml 2% (v/v) glutaraldehyde in 0.1M phosphate buffer at 
4°C overnight.
The glutaraldehyde fixative was removed by washing the samples 
three times in 0.1M phosphate buffer (1ml) with centrifugation for 7 
min in a bench microfuge, at low speed. The lipids in the samples 
were fixed with 1ml 1% osmium, in 0.1M phosphate, for 1 hr at room 
temperature. The osmium fixes the lipids by cross-linking with the
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unsaturated bonds in the lipids. This cross-linking with osmium 
imparts some contrast as it is electron dense. Once the samples were 
fixed the excess osmium was removed by washing three times with 
distilled water with centrifugation, as above. The samples were 'en 
bloc' stained with 2% uranyl acetate for 30 min at room temperature 
in the dark, as uranyl acetate is light sensitive. The excess uranyl 
acetate was removed by washing three times with distilled water 
followed by centrifugation as before.
The samples were then dehydrated through a series of acetones, 
50%, 70%, 90% and 100% (2x5 min at each concentration with 
centrifugation for 7 min at 3,000g). The acetone concentration was 
increased gradually to ensure complete dehydration of the samples.
The samples were placed in Taab (medium hardness) Epoxy resin (50% 
v/v in 100% acetone) and left at room temperature overnight. The 
samples were infiltrated with 100% resin (twice, with centrifugation) 
and left in 100% resin for 4-6 hr at room temperature before adding 
lml 100% resin and curing the samples in an oven (70°C) for 48 hr. 
Once cured the samples were sectioned on a Reichert 0MU3 
ultramicrotome using a glass cutter. The colour of the section 
reflects its thickness and only sections which were silver/gold in 
colour (approximately 90nm) were taken and placed on copper grids.
The sections were stained, before viewing, by floating the grids 
on drops of 2% uranyl acetate for 7 min at room temperature, in the 
dark. Uranyl acetate was removed from the grids by washing four 
times on drops of distilled water before being placed on drops of 
Reynolds' lead citrate (Reynolds, 1963) for 7 min at room 
temperature. The lead citrate stain was applied in the presence of
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0.1M NaOH which absorbs carbon dioxide from the air thus preventing 
the precipitation of lead carbonate. The lead acts as a general 
stain as it attaches to bound osmium in the membrane enhancing the 
contrast (Marinozzi, 1963). The excess lead citrate was removed by 
washing four times on drops of distilled water. The grids were then 
allowed to dry on filter paper and the sections were viewed and 
photographed on a 1200EX or 2000FX electron microscope.
Prints were made using Ilford multigrade paper and developed in 
Ilford multigrade developer for 2 min. The prints were then placed 
in a stopbath, water with a few drops of acetic acid, for 5-10s 
before the image was fixed in a solution of Ilford Ilfospeed fixer 
for 5-10 min. Excess reagents were washed away by a continual flow 
of water (for at least 15 min) before the prints were dried.
4.3. RESULTS AND DISCUSSION
4.3.1. Protein distribution across the Percoll gradient
When the SI supernatant from the rat hippocampal homogenate was 
separated on Percoll gradients five major subcellular fractions were 
obtained (interfacial fractions F1-F4 and a pellet F5; see fig. 4.1). 
The protein concentration of each fraction was determined, see 
table 4.1.
35.5% of the SI supernatent was recovered in the washed 
fractions (twice in Krebs buffer, see methods 4.2.1.) from the 
Percoll gradient. This low protein recovery probably reflects losses 
due to washing. Fraction F2 had two to five times more protein than 
any other fraction, which accounted for 44% of the recovered protein. 
A similar protein distribution was reported by Dunkley et al .(1988)
116
FRACTION PROTEIN RECOVERY
mg/g vet weight (% SI)
SI 41.15 ± 2.7 (100)
FI 1.71 ± 0.4 4.2
F2 6.37 ± 0.4 15.5
F3 3.37 ± 0.2 8.2
F4 2.00 ± 0.3 4.9
F5 1.15 ± 0.1 2.8
Table 4.1. Protein distribution of the SI supernatant on 
Percoll gradients. Values are the mean ± SEM of 6 experiments
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for the separation of rat cortical SI supernatant on Percoll 
gradients Jj»re 44.7% of the protein was recovered, the majority of 
which (42%) was present in fraction F2. This similarity with the 
work of Dunkley et al.n(1988) shows that the procedure has been 
reproduced for use with this discrete brain region.
4.3.2. Lactate dehydrogenase activity
Each fraction from the Percoll gradient was assayed for LDH 
activity (fig. 4.2), a high occluded LDH level indicates enrichment 
of synaptosomes in the fraction (Marchbanks, 1967).
As expected, the SI supernatant had a high level of free LDH, 
only 20% of the total LDH activity was occluded, due to cytoplasmic 
LDH which was released during homogenisation. 81% of the SI occluded 
LDH activity was recovered in the fractions from the gradient. 
Fraction FI, like the SI fraction, had a high level of free LDH 
activity with only 20% of the total LDH activity occluded. Fraction 
FI contains mainly myelin and membrane fragments, as shown by 
electron microscopy (Dunkley et al., 1988; section 4.3.6., fig. 4.8E)
and is consistent with a low level of occluded LDH activity. A large
amount of the free LDH from broken cells is present at the top of the 
gradient.
Fractions F2, F3 and F4 all had approximately 80% of the total 
LDH activity occluded, suggesting high concentrations of synaptosomes 
in these fractions. Electron microscopy (Dunkley et al., 1988; 
section 4.3.6., fig. 4.8F, G and H) shows a high synaptosomal content 
in these fractions. The synaptosome fraction, PB, from the sucrose 
gradient had a similarly high occluded LDH level (80%; section
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Fig. 4.2. LDH activity in fractions from the Percoll gradient. 
Enzyme activity was assessed by measuring the oxidation of NADH at 
340nm, with pyruvate as substrate, in the presence (total LDH) or 
absence (free LDH) of Triton X-100. Occluded levels were calculated 
as the difference between total and free LDH. Values are the mean ± 
SEM, n=8.
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3.3.1.)* The low LDH activity in fraction F5, 38% of which was 
occluded, suggests that the synaptosomal concentration in this 
fraction was small. The low level of occluded LDH in fraction F5 
could indicate that the synaptosomes may not be as structurally 
intact, after washing, as those in the other fractions thus fraction 
F5 would have a relatively high level of free LDH. Electron 
microscopy showed (Dunkley et al., 1988; section 4.3.6., fig. 4.81) 
that this fraction contained mainly extrasynaptosomal mitochondria.
This LDH distribution closely parallels that reported for the 
synaptosomal marker synapsin 1 (Dunkley et al., 1988). The high 
level of synapsin 1 activity in fraction F2 was due, in part, to 
fragments of synaptic plasma membrane present in the fraction as 
fraction F3 and F4 had higher functional synaptosomal activities. As 
shown in fig. 4.8F, fraction F2 contains empty membrane sacs which 
could entrap LDH before resealing thus giving an usually high LDH 
activity in this fraction.
4.3.3. Acetylcholinesterase activity
4.3.3.1. Activity across the Percoll gradient
Distribution of AChE activity across the Percoll gradient was 
used as a marker for cholinergic terminals in the fractions, 
fig. 4.3. Of the AChE activity in the SI supernatant, 65% was 
recovered from the Percoll gradient in fractions F1-F5.
Although AChE activity was found in all gradient fractions, 
there was a significant enrichment in fractions F1-F4 relative to SI. 
The slightly higher activity in fraction FI could be due to a greater 
abundance of membrane fragments, see fig. 4.8E. Fraction F5 appeared
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Fig. 4.3. AChE activity in fractions from the Percoll 
gradient. Enzyme activity was assessed by measuring the hydrolysis 
of acetyl thiocholine in the presence of DTNB at 412nm. Values are 
the mean + SEM, n=4. Significantly different from the SI 
supernatant, * p<0.05, ** p<0.005, *** p<0.001.
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to have a lower AChE activity and probably reflects its high 
extrasynaptosomal mitochondrial and low plasma membrane content, see 
fig. 4.81.
This ubiquitous distribution of AChE across the Percoll gradient 
shows that AChE activity is not a specific marker for cholinergic 
nerve terminals. Indeed, AChE activity has been reported in brain 
regions where there is little ACh (Eckenstein & Sofroniew, 1983) and 
in non-cholinergic and non neuronal cells; for example: 
erythrocytes, plasma, blood vessels and placenta (Small, 1989). Thus 
AChE activity alone is not a very specific indication of the 
cholinergic nature of the gradient fractions.
4.3.3.2. Acetylcholinesterase inhibition by BV284C51
When studying ACh release it is not advantageous to have AChE 
present, which breaks down ACh to Ch and acetate. In order to study 
nicotine-evoked ACh release from hippocampal slices, 
eletrophysiologically (see chapter 6), AChE activity was inhibited 
using the specific AChE inhibitor, BW284C51 (Mizobe & Livett, 1982). 
To determine what concentration of BW284C51 was needed to block AChE 
activity, the AChE assay was carried out in the presence of varying 
BW284C51 concentrations. The SI supernatent was used as it gives a 
better representation of the enzyme activity in the hippocampus than 
any one of the fractions from the Percoll gradient.
From the inhibition curve, fig. 4.4a, maximal inhibition of AChE 
was approximately 90% and was achieved at an inhibitor concentration 
of lyM or greater. Thus a BW284C51 concentration of lpM or higher 
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Fig. 4.4a). An inhibition curve of AChE activity by varying 
BW284C51 concentrations. The effect of BW284C51 concentration on the
AChE activity of the SI supernatent was measured by monitoring the
hydrolysis of acetyl thiocholine in the presence of DTNB at 412nm.
Values are the mean ± SEM, n=4.
Fig. 4.4 b). A Hill plot of AChE activity against BW284C51
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the concentration to achieve half maximal inhibition, was 7.4nfi 
estimated from the inhibition curve, fig. 4.4a. A more accurate IC50 
value of 5.6nf1was obtained from a Hill Plot, fig. 4.4b, where P is 
the percent of AChE activity in the absence of BW284C51.
4.3.4. Choline acetyltransferase activity
The cholinergic nature of the Percoll gradient fractions was 
further investigated by assessing the ChAT activity across the 
gradient.
4.3.4.1. Concentration of bromoacetylcholine
As White & Wu (1973) reported that carnitine acetyltransferase 
will acetylate Ch to ACh, when carnitine levels are low, the 
contribution of this enzyme to the ACh level produced in the ChAT 
assay, see section 4.2.5., was determined. Morris & Grewaal (1971) 
reported that bromoacetylcholine (62.5yM) inhibited ChAT activity by 
70%, but Kasa & Morris (1972) observed that lOmM bromoacetylcholine 
caused a 77% ChAT inhibition. Roskoski et al..(1974) stated that 
O.lmM bromoacetylcholine inhibited 61% of the ChAT activity and that 
this inhibitor had no effect on carnitine acetyltransferase activity. 
Thus bromoacetylcholine appears to be a specific inhibitor of ChAT 
activity. The concentration of bromoacetylcholine to use was 
determined by assaying for ChAT activity in the presence of varying 
concentrations (0.01-10mM) of the inhibitor, see fig. 4.5. The SI 
supernatant was used, as the ChAT activity would be greater in this 
fraction than any one from the gradient and so a bromoacetylcholine 
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Fig. 4.5. The effect of bromoacetylcholine concentration on
ChAT activity. The level of ACh produced by the SI supernatent in 
the presence of varying bromoacetylcholine concentrations (0.01-10mM) 
was measured as described in the methods section 4.2.5.
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From fig. 4.5, the maximum inhibition of ChAT activity in the SI 
supernatant (482 of the control, no bromoacetylcholine) was achieved 
with O.lmM bromoacetylcholine. It was this concentration that was 
used to determine non-specific acetyltransferase activity in the 
fractions from the Percoll gradient. At bromoacetylcholine 
concentrations of 1.75mM and greater the inhibitor appears to act as 
a substrate in the assay as levels of radiolabelled product increase 
above those of the control, that has no bromoacetylcholine.
4.3.4.2. Choline acetyltransferase activity across the 
Percoll gradient
ChAT activity in the gradient fractions was determined as 
described in section 4.2.5, non-specific acetyltransferase activity 
was determined in the presence of O.lmM bromoacetylcholine, see 
fig. 4.6.
Approximately 622 of the SI ChAT activity was recovered in the 
gradient fractions, with fractions F4 and F5 having the highest ChAT 
activity/mg of protein. The high mitochondrial and low synaptosomal 
content (shown by low occluded LDH activity, fig. 4.2, and electron 
microscopy, fig. 4.81) of fraction F5 suggests that some of the ACh 
produced could be as a result of non-specific acetyltransferase 
activity. In the presence of bromoacetylcholine, non-specific 
acetyltransferase activity accounted for 302 of the ACh produced in 
fraction F5 which was approximately twice that of fraction F4. ChAT 
has been reported to bind to membranes (Rylett, 1989) under certain 
conditions of pH and ionic strength (Fonnum, 1967) which could 
account for high residual ChAT activity in fraction F5, considering 
the low synaptosomal content.
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Fig. 4.6. ChAT activity in fractions from the Percoll gradient. 
The level of ACh produced was determined as described in the methods 
(section 4.2.5). Non-specific acetyltransferase activity was 
determined in the presence of O.lmM bromoacetylcholine. Values are 
the mean ± SEM, n=6. Significantly different from the total activity 
in the SI supernatant, * p<0.001.
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Fraction FI has a low synaptosomal content (low occluded LDH, 
fig. 4.2; electron microscopy, fig. 4.8E) and so as expected had a 
low ChAT activity. The lower ChAT activity in fractions F2 and F3, 
compared to fraction F4, indicates that although there is a high 
synaptosomal content, as shown by high occluded LDH levels (fig. 4.2) 
and electron microscopy, fig. 4.8F and G, only a small proportion of 
these synaptosomes are cholinergic in nature. AChE activity in the 
presence of ChAT is specific for cholinergic terminals but, as shown 
by the ubiquitous AChE distribution across the gradient (fig. 4.3), 
AChE activity alone has a low cholinergic specificity.
The high synaptosomal content but low level of ChAT activity in 
fractions F2 and F3 lends to the possibility of isolating 
subpopulations of synaptosomes, based on transmitter type, in 
different fractions from the Percoll gradient. However, studies with 
five different transmitters have shown that such subdivision of 
synaptosomes does not occur. Dopamine (Robinson & Lovenberg, 1986), 
noradrenaline (Dunkley et al., 1987, 1988), GABA (Thorne et al.,
1988) and ACh (this report) markers all have highest activity in 
fraction F4. Only 5HT (Robinson & Lovenberg, 1986) had a higher 
specific activity in another fraction, fraction F3.
4.3.5. Choline uptake across the gradient
In order for ChAT to produce ACh there needs to be a supply of 
3
Ch, and [ H]Ch uptake was used as a functional assessment of 
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Fig. 4.7. [ H]Ch uptake by fractions from the Percoll gradient. 
After incubation with 0.8pM [^H]Ch for 20min at 37°C, samples (100pl) 
were withdrawn, filtered and washed. Non-specific uptake was 
determined in the presence of HC-3 (lyM). Values are the mean ± SEM, 
n=4. S was the uptake into the sucrose synaptosome fraction, under 
the same conditions.
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Fraction FI had little specific Ch uptake (10 pmol/20 min/mg 
protein) corresponding to a low synaptosome content, as shown by low 
occluded LDH levels (fig. 4.2) and electron microscopy (fig. 4.8E).
Ch uptake into fraction F2 (19 pmol/20 min/mg protein) was low 
considering the ChAT activity in this fraction (fig. 4.6), as Ch 
uptake has been reported to be associated with ChAT activity 
(Yamamura & Snyder, 1973). This adds support to the suggestion that 
the cholinergic nature of these fraction F2 synaptosomes is low. 
Fraction F3 had a significant amount of Ch uptake (59 pmol/20 min/mg 
protein) which corresponds with the ChAT activity in this fraction 
(fig. 4.6). The Ch uptake into fraction F3 was approximately three 
times higher than that into fraction F2 even though the ChAT activity 
was almost equivalent. The high ChAT activity in fraction F2 could 
be due to the enzyme being bound to membranes (Fonnum, 1967) in this 
fraction. The highest Ch uptake (157 pmol/20 min/mg protein) was 
found in fraction F4, which correlates with the high ChAT activity in 
this fraction. This Ch uptake into fraction F4 was almost three 
times that taken into fraction F3. Specific Ch uptake into fraction 
F5 was low (15 pmol/20 min/mg protein) adding to the suggestion that 
the ACh produced in this fraction (fig. 4.6) was from non-specific 
acetyltransferases, for example carnitine acetyltransferase, or from 
membrane bound ChAT activity.
From these markers fraction F4 is more enriched in cholinergic 
terminals than any other fraction from the gradient. Fraction F4 has 
high occluded LDH levels showing a large synaptosomal content which 
has the greatest ChAT activity and Ch uptake as well as having AChE 
activity. There was low occluded LDH, ChAT activity and Ch uptake in 
fraction FI indicating a small number of cholinergic synaptosomes.
130
The high AChE levels in this FI fraction are probably due to enzyme 
bound to membrane fragments. Although fractions F2 and F3 have a 
high synaptosomal content, from LDH activity, few are cholinergic in 
nature. Fraction F3 had slightly greater ChAT activity and Ch uptake 
than fraction F2. The low occluded LDH levels in fraction F5 
indicated a small synaptosomal content which exhibited low levels of 
AChE activity and Ch uptake indicating a small number of cholinergic 
terminals. Although ChAT activity in fraction F5 was relatively high 
this could be as a result of enzyme binding to membranes or 
non-specific acetyltransferases giving an incorrect value for ChAT 
activity.
After a 20 min incubation, at 37°C, with 0.8pM [ H]Ch specific 
uptake into fraction F4 (157 pmol/20 min/mg protein) was four to five 
times greater than that into sucrose isolated synaptosomes (35 
pmol/20 min/mg protein), see fig. 4.7. This suggests that fraction 
F4 from the Percoll gradient is a purer synaptosome preparation for 
studying cholinergic function than the sucrose synaptosome fraction, 
even though both had a similar occluded LDH level (80% of total LDH).
Non-specific uptake was approximately equivalent in both 
fraction F4 and the sucrose isolated synaptosomes.
4.3.6. Electron microscopy
Having characterised the fractions from the Percoll gradient 
biochemically they were further studied morphologically by electron 
microscopy along with the fractions from the sucrose gradient.
Prints from each fraction are shown in fig. 4.8A-I.
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Fig. 4.8. Electron micrographs of fractions from the sucrose and 
Percoll gradients.
Al. The sucrose PA fraction. Myelin (MY), resealed vesicles 
(RV) and some synaptosomes (SY) can be seen. Bar = lym.
A2. A high magnification of fraction PA. This high power 




Bl. The sucrose PB fraction. This fraction contains 
synaptosomes (SY) with synaptic vesicles (V) and mitochondria (M), 
also extrasynaptosomal mitochondria (EM) and resealed vesicles (RV). 
Bar = 200nm.
B2. A high magnification of a PB fraction synaptosome* At this 




Cl. The sucrose PC fraction. At this low magnification a 
nucleus (N), extrasynaptosomal mitochondria (EM) and membrane 
fragments (MF) can be seen. Bar = lym.
C2. A high magnification of the PC fraction. Many resealed 
vesicles (RV) are present though few contain vesicles (V) and/or 
mitochondria (M). Bar = 200nm.
V>  ■<
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D. The Percoll SI supernatant. Synaptosomes (SY), containing 
vesicles (V) and mitochondria (M), and many resealed vesicles (RV) 
are present. Bar = 200nm.
E. The Percoll FI fraction. This fraction has myelin (MY) and 
many resealed vesicles (RV). Bar = 200nm.
E
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F. The Percoll F2 fraction. Depicted are synaptosomes (SY), 
containing both synaptic vesicles (V) and mitochondria (M), and also 
empty resealed vesicles (RV). Bar = 200nm.
G. The Percoll F3 fraction. Contents include synaptosomes (SY) 
with synaptic vesicles (V) and mitochondria (M), also present are 
resealed vesicles (RV). Bar = 200nm.
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HI. The Percoll F4 fraction. Present in this fraction are 
synaptosomes (SY), containing vesicles (V) and mitochondria (M), and 
also extrasynaptosomal mitochondria (EH). Bar = 200nm.
H2. A higher magnification of a fraction F4 synaptosome.
Within the synaptosome (SY), both synaptic vesicles (V) and 
mitochondria (M) can be seen. Bar = lOOnm.
H2
I. The Percoll F5 fraction. This fraction has a high 
extrasynaptosomal mitochondrial (EM) content. Bar * 200nm.
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4.3.6.1. The sucrose gradient
The electron micrographs of the fractions from the sucrose 
gradient (see fig. 3.1) are shown in fig. 4.8A-C. In fig. 4.8A1 it 
can be seen that the FA fraction contains a large amount of myelin 
(MY) which as expected would be at the top of the gradient. The high 
power electron micrograph, fig. 4.8A2, shows the distinctive lamellae 
(L) of the myelin. Abundant within this PA fraction are small empty 
resealed vesicles (RV). A few of these structures contained smalled 
synaptic vesicles and so were thought to be synaptosomes (SY). The 
low occluded LDH levels (fig. 3.3) in this fraction was as a result 
of a low synaptosomal content. The high free LDH levels in this 
fraction was due to cytoplasm at the top of the gradient.
The PB fraction, fig. 4.8B1, contained a higher proportion of 
synaptosomes (SY) containing synaptic vesicles (V) and mitochondria 
(M). This high synaptosome content would give the high occluded LDH 
activity seen in fig. 3.3. There were also many empty resealed 
vesicles (RV) and extrasynaptosomal mitochondria (EM) indicating a 
crude synaptosome preparation. Fig. 4.8B1 is a "dirtier" print due 
to specks of lead carbonate which precipitated during staining of the 
sections, see section 4.2.11. A high power view of a synaptosome was 
depicted in fig. 4.8B2 showing synaptic vesicles (V) and a 
mitochondrion (M).
Fig. 4.8C1 shows the contents of the PC fraction which are many 
extrasynaptosomal mitochondria (EM), large membrane fragments (MF) 
and a nucleus (N). A higher magnification of this fraction, 
fig. 4.8C2, showed many resealed vesicles (RV) though few contained 
synaptic vesicles (V) and/or mitochondria (M). As there is a low
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synaptosome content in this fraction the occluded LDH levels were 
low, see fig. 3.3.
This distribution of subcellular organelles on the sucrose 
gradient is similar to that described by Gray & Whittaker (1962) in 
that the PA fraction contained mainly myelin and the PB fraction 
mostly synaptosomes. However, in the method of Gray & Whittaker the 
nuclei were first pelleted and discarded before layering the P2 
pellet on a sucrose gradient, and so the PC fraction in this 
procedure has a slightly different composition.
4.3.6.2. The Percoll gradient
The SI supernatant, fig. 4.8D, contained many resealed vesicles 
containing synaptic vesicles (V) and/or mitochondria (M) and were 
probably synaptosomes. There were also smaller empty resealed 
vesicles (RV) and some myelin, not shown in the print. The FI 
fraction (fig. 4.8E) contained mainly myelin (MY) and empty resealed 
vesicles (RV). The high free LDH activity in this fraction (see 
fig. 4.2) is probably due to cytoplasm remaining at the top of the 
gradient. With a low synaptosomal content the occluded LDH, ChAT 
activity and Ch uptake was small. The high AChE activity in this 
fraction is probably as a result of membrane bound enzyme, possibly 
on postsynaptic membrane fragments.
Fractions F2 (fig. 4.8F) and F3 (fig. 4.8G), contained many 
synaptosomes (SY) with synaptic vesicles (V) and mitochondria (M). 
Unidentified resealed vesicles (RV) were also present in both 
fractions. Fraction F4, fig. 4.8H1, contained a higher proportion of 
synaptosomes (SY) than resealed vesicles (RV) than fractions F2 and
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F3 though it had more extrasynaptosomal mitochondria (EM).
Fig. 4.8H2 shows a higher magnification of a fraction F4 synaptosome. 
Fraction F5, fig. 4.81 contained mostly extrasynaptosomal 
mitochondria (EM) which could explain the unexpected high levels of 
ACh produced in the Chi^ T assay (fig. 4.6) being due to non-specific 
acetyltransferase activities of the mitochondria, for example 
carnitine acetyltransferase.
As reported by Dunkley et al. (1988) fraction FI was richer in 
myelin whereas fraction F5 had the highest extrasynaptosomal 
mitochondrial content than any other fraction. Synaptosomal content 
of the fractions increased across the gradient, fractions F1-F4, with 
enrichment in fraction F4.
4.3.7. Choline uptake into fraction F4
Having established that fraction F4 from the Percoll gradient
3
was enriched in cholinergic synaptosomes the parameters for [ H]Ch 
uptake into this fraction were optimised.
4.3.7.1. The effect of incubation time
3
The effect of incubation time on [ H]Ch uptake (0.8yM) was 
studied over a period of 0-60 min at 37°C, see fig. 4.9.
Non-specific uptake, at 4°C, was essentially linear with time 
and accounted for only 2% of the total Ch taken up. Non-specific 
uptake at 4°C (2 pmol/20 min/mg protein) was lower than in the 
presence of HC-3 (lyM; 13 pmol/20 min/mg protein) as non-selective 
transport systems as well as HAChT are probably blocked at 4°C. 
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Fig. 4.9. The time course of [ H]Ch uptake by Percoll fraction
3
F4. After the addition of [ H]Ch (0.8yM), samples were incubated at 
37°C and at time intervals (0-60min) lOOyl were taken, filtered and 
washed. Non-specific uptake was determined at 4°C. The values for 
total (•), specific (A) and non-specific (y ) uptake are the mean ± 
SEM, n=4.
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uptake) approached maximal at 30 min. Thus sufficient labelling of 
synaptosomes could be achieved by a 20 min incubation and this was 
used in future experiments.
4.3.7.2. The effect of choline concentration
3
The dependence of [ H]Ch uptake on Ch concentration was studied 
over the range 0.1-2.0yM, see fig. 4.10.
Non-specific uptake, at 4°C, was essentially linear with time 
and again accounted for about 2X of the total Ch taken up. Specific 
uptake approached saturation at lyM and so sufficient labelling of 
the synaptosomes could be achieved at a Ch concentration of 0.8yM and 
this was used in future experiments. Examination of the time course 
(fig. 3.4 and fig. 4.9) and Ch concentration dependence (fig. 3.5 and
3
fig. 4.10) of [ H]Ch uptake confirmed that a 20 min incubation, at 
37°C, with 0.8yM Ch was optimal for labelling synaptosomes from both 
the sucrose and Percoll gradients.
Using a direct linear plot, not shown, a Kt value of 0.51pM (the 
concentration for half maximal transport) and a Vmax of 173.8 pmol/
20 min/mg protein were obtained for uptake into fraction F4. The Kt 
value was equivalent to that obtained for uptake into sucrose 
isolated synaptosomes, see section 3.3.2.2., which was as expected as 
there is no change in the transport system with a different isolating 
medium and within the range reported for specific HAChT into 
hippocampal synaptosomes: 0.43-0.90yM (Sorimachi & Kataoka, 1974;
Atweh et al., 1975; Murrin & Kuhar, 1976; Simon & Kuhar, 1976; Simon 
et al., 1976). The F4 fraction Vmax value (173.8 pmol/20 min/mg 
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Fig. 4.10. The effect of Ch concentration on [ H]Ch uptake by
3
Percoll fraction F4. Samples were incubated with varying [ H]Ch 
concentrations (0.1-2.0pM) and after 20 min at 37°C, 100yl were 
taken, filtered and washed. Non-specific uptake was determined at 
4°C. The values for total (#), specific (A) and non-specific (▼) 
uptake are the mean ± SEM, n=4.
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sucrose isolated synaptosomes (34.5 pmol/20 min/mg protein). This 
suggests that the Percoll method produces an enriched functional 
synaptosome preparation for studying cholinergic terminals compared 
to the sucrose procedure. From fig. 4.9 a Vmax of 42.5 pmol/4min/mg 
protein was obtained which is within the range reported by those 
named above (16-56.4 pmol/4 min/mg protein). The Vmax at 4 min was 
used, as uptake at this time interval was still linear.
3
4.3.8. The percent acetylation of [ H]Ch in fraction F4
3
Having obtained the optimum [ H]Ch uptake conditions, the
3
percent acetylation of this accumulated [ H]Ch was determined to give 
an indication of the proportions of radioactivity associated with Ch 
and ACh in the fraction F4 synaptosomes. The choline bases were 
first extracted from the synaptosomes and then separated by thin 
layer chromatography.
From the samples taken at steps (1-3) throughout the extraction 
procedure 62% of the radioactivity in the perchloric acid was 
extracted by TPB/heptan2one. Of this radioactivity, 85% was 
extracted by HC1. These values are similar to those reported by 
Fonnum (1969).
The choline bases, Ch and ACh, could be separated by thin layer
chromatography as shown in fig. 4.11. The standard Ch and ACh spots
had Rf values of 0.37 and 0.49, respectively, see table 4.2, which
correlates well with those reported by Augustinsson & Grahn (1953) of
0.37/0.38 for Ch and 0.46/0.47 for ACh. The choline bases of the
3
extracted samples (F4: [ H]Ch loaded fraction F4 synaptosomes; F2:
3
control, fraction F2 synaptosomes with added [ H]ACh) had higher Rf
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Fig. 4.11. A schematic diagram of an eluted thin layer 
chromatography plate. Samples, in a carrier solution, were eluted in
butan-l-ol:ethanol:glacial acetic acid:distilled water (8:2:1:3 by
3
vol). Ch was [ H]Ch, F4 were the extracted test samples, F2 were the
3




Rf VALUE ^RADIOACTIVITY 
IN ACh SPOT
[3H]Ch Ch 0.39 ± 0.04
2.4 ± 0.8
STANDARD ACh 0.51 ± 0.03
F4 Ch 0.55 ± 0.01
101.0 ± 1.6
TEST ACh 0.63 ± 0.01
F2 Ch 0.55 ± 0.01
69.2 ± 1.0
CONTROL ACh 0.63 ± 0.01
[3H]ACh Ch 0.36 ± 0.02
96.6 ± 0.2
STANDARD ACh 0.48 ± 0.02
Table 4.2. Separation of Ch and ACh on thin layer
chromatography plates. This was used to determine the percent
radioactivity associated with ACh in each of the test (F4) and
control (F2) samples (in quadruplicate, n=2 independent extractions), 
3 3also in [ H]ACh and [ H]Ch standards (in duplicate, n=2 experiments). 
Values are the mean ± SEM.
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values than the standards, see table 4.2, probably due to the 
presence of some residual solvent, from the extraction procedure.
3
From table 4.2, the [ H]ACh used as the standard and in the F2
control samples was shown to be 96.6% ACh suggesting that Ch
acetylation with acetic anhydride (see section 3.2.7., for synthesis
3
of [ H]ACh) was almost 100% efficient. During the extraction process 
this ACh was hydrolysed by 30% as only 70% of the radioactivity in 
the F2 control samples was associated with the ACh spot. Taking into 
account this hydrolysis, the acetylation of Ch in the F4 test samples 
was 98%, once the percent crossover of radioactivity (2.4%, see
3
[ H]Ch standard) had been considered. This high acetylation is in 
agreement with the suggestion of Barker & Mittag (1975) and Benishun 
& Carroll (1981) that ChAT activity and HAChT are coupled in the
nerve terminal. Similarly high acetylations of Ch to ACh have been
reported: 69% (Wonnacott & Marchbanks, 1976); 75% (Moss & Wonnacott,
1985); 87% (Rowell & Winkler, 1984); 91% (Wong & Prince, 1978). Thus 
with such a high acetylation most if not all of the radioactivity
3
collected from the superfusion system would be expected to be [ H]ACh
3
and this was shown to be so in section 3.3.3.1.4., where [ H]ACh was
3
separated from [ H]Ch by an enzymic extraction procedure.
4.3.9. Superfusion of synaptosomes isolated on sucrose and 
Percoll gradients
The functional responsiveness of synaptosomes isolated on 
sucrose (PB fraction) or Percoll (fraction F4) gradients were 
compared by superfusion. ACh release from synaptosomes, derived from
the same homogenate by either method, was monitored after loading
3 3with [ H]Ch under identical conditions. Excess [ H]Ch was removed by
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centrifugation with an equal volume of Krebs buffer before equal 
amounts of protein (approximately 150yg) were loaded into the 
superfusion chambers, see fig. 3.2, two chambers contained Percoll 
fraction F4 and two chambers contained sucrose synaptosomes. The 
synaptosomes were continually perfused with Krebs buffer and 
subjected to 20s pulses of drug (lOyM nicotine, SI, S2; Krebs buffer, 
S3; 20mM K+, S4) at 30 min intervals after an initial washout period 
of 40 min. The collected fractions were than counted in the presence 
of scintillant, see fig. 4.12 and table 4.3.
From fig. 4.12 it is clear that release from Percoll fraction F4 
was greater than that from sucrose synaptosomes. Fraction F4 has a 
higher basal release than the sucrose synaptosomes which is
3
proportional to the higher [ H]Ch uptake in this fraction (157 
pmol/20 min/mg protein in fraction F4, 35 pmol/20 min/mg protein in 
sucrose synaptosomes, see section 4.3.5. and fig. 4.7). Nicotine 
evoked ACh release was four to five times greater from fraction F4 
than from sucrose synaptosomes showing that the Percoll method 
produces a purer synaptosome preparation for studying cholinergic 
function. The response to air bubble in the sucrose synaptosome was 
approximately 442 of the SI nicotine response whereas in fraction F4 
the response was 322 of the SI (determined by S3/S1 ratios). This 
reduction in air bubble effect probably reflects the increase in 
response of the purer synaptosome population in fraction F4. A 
similar decrease in air bubble effect with increase in response was 
seen in section 3.3.3.4.3. where 10yM nicotine evoked a greater ACh 
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Fig. 4.12. Superfusion profiles of ACh release from (#)
Percoll fraction F4 and (A) sucrose isolated synaptosomes. After a 
40 min washout period the synaptosomes were subjected to successive 
stimulations with: nicotine (10yM; SI, S2), Krebs buffer (S3) and K+ 
(20mM, S4) at 30 min intervals. | Indicates pulse arriving at the 
synaptosomes. Numbers in brackets are fmol ACh released/mg protein.
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SI S2 S3 S4
NICOTINE NICOTINE KREBS K+
10yM lOyM BUFFER 20mM
SUCROSE 62.0 53.8 27.5 117.4
± 2.5 ± 3.3 ± 2.4 ± 1.4
PERCOLL 290.0 240.4 93.1 450.0
± 4.7 ± 4.4 ± 3.2 ± 4.2
Table 4.3. Evoked ACh release from sucrose or Percoll 
isolated synaptosomes. Release was provoked by nicotine (lOyM; SI, 
S2), Krebs buffer (S3) or K+ (20mM; S4) and values are expressed as 
fmol ACh released/mg protein ± SEM. The values are the mean of 3 
separate experiments.
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The greater response to stimulation in fraction F4 will make 
differences in drug evoked ACh release easier to determine than using 
sucrose synaptosomes, where the response is much smaller. Thus 
fraction F4 provides a pure, highly functional cholinergic 
synaptosome preparation for studying nicotine evoked ACh release and 
so this synaptosome fraction from the Percoll gradient was used in 
future experiments.
4.4. SUMMARY
Due to the low nicotine evoked ACh release from sucrose isolated 
synaptosomes, the use of Percoll for synaptosome isolation was 
investigated to determine if a purer cholinergic synaptosome 
population could be obtained. The method used was that described by 
Dunkley et al., (1987, 1988) for the preparation of cortical 
synaptosomes and this was applied for use with the hippocampus. A 
similar protein distribution (table 4.1) and subcellular organelle 
content of fractions across the gradient showed that the procedure 
had been faithfully reproduced for this discrete brain region.
Five fractions were obtained from the Percoll gradient and the 
cholinergic nature of these were examined. Fraction FI had a low 
synaptosomal content (from LDH, fig. 4.2 , and electron microscopy, 
fig. 4.8E) and so had low levels of the cholinergic markers ChAT and 
Ch uptake. The high AChE activity in this fraction was probably as a 
result of postsynaptic membrane fragments, with bound enzyme, being 
present in the FI fraction. Although fractions F2 and F3 exhibited 
high levels of synaptosomes (from LDH and electron microscopy) 
cholinergic markers were relatively low (ChAT and Ch uptake; 
activities were higher in fraction F3 than F2) and so there was no
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apparent cholinergic enrichment in these fractions. The highest 
cholinergic synaptosome content was in fraction F4, the activities of 
which were at least two to threefold greater than any other fraction.
Fraction F5 had a low synaptosome content (from LDH and electron
microscopy) with a correspondingly low functional cholinergic 
3
activity ([ H]Ch uptake). The apparently high ChAT activity of this 
fraction is probably due, in part, to non-specific acetyltransferase 
activity like carnitine acetyltransferase.
The response of Percoll fraction F4 to nicotine stimulation was 
compared with that of sucrose synaptosomes, by superfusion. The 
evoked ACh release was four times greater from fraction F4 than from 
sucrose synaptosomes. Thus the Percoll method produces an enriched 
cholinergic population of synaptosomes for the study of nicotine 
evoked ACh release.
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CHAPTER 5. NICOTINE-EVOKED ACETYLCHOLINE RELEASE FROM SYNAPTOSOMES 
ISOLATED ON PERCOLL GRADIENTS
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5.1. INTRODUCTION
The Percoll gradient method produces a highly purified 
synaptosome preparation for studying cholinergic function (see 
chapter 4), Nicotine evoked ACh release, from these synaptosomes, 
was studied using a modified version of the superfusion system of 
Rapier et al., (1988) as outlined in section 3.3.4.
The effect of nicotine concentration on ACh release was examined 
and the nicotinic nature of this response was studied using DHfSE.
The dependency of this evoked release on the presence of Ca++ ions 
was also ascertained.
As mentioned in section 1.2.4., the AChE inhibitors THA and 
physostigmine have both been used therapeutically, in SDAT, to 
increase ACh levels. Although there have been reports of moderate 
(THA; Summers et al., 1986) or transient (physostigmine; Christie 
et al., 1981) improvements in memory-related tasks in SDAT, the mode 
of action of these drugs may not be limited to enzyme inhibition. As 
it has been observed that both THA (Perry et al., 1988) and 
physostigmine (Shaw et al., 1985) interact directly with the nAChR. 
Thus the effects of these AChE inhibitors on nicotine-evoked ACh 
release was studied, by superfusion, to determine whether the mode of 
action was via the receptor.
5.2. METHODS
Hippocampal synaptosomes were prepared and isolated on four step 
Percoll gradients, as described in section 4.2.1. The F4 fraction 
was removed and washed twice with Krebs buffer (10ml; 15 min at 
15,000g) to remove the Percoll. The pellet was resuspended in 1ml
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3
Krebs buffer and then loaded with [ H]Ch (0.8yM; 20min at 37°C).
3
Excess [ H]Ch was removed by washing with Krebs buffer (1ml) followed 
by centrifugation (7 min at 3,000g) before resuspension in Krebs 
buffer (1ml) and samples (150yl) placed in superfusion chambers (see 
section 3.2.5.; fig. 3.2).
The synaptosmes were superfused with Krebs buffer and subjected 
to an inital nicotine pulse (lOyM; SI), to standardise the chambers, 
after a 40 min washout period. The effect of nicotine concentration 
on ACh release was studied by varying the concentration (l-100yM) in 
the S2 pulse. The nicotinic nature of this response was studied by 
introducing buffer, containing the nicotinic agonist DH$E (lOyM) 15 
min after the SI pulse. The subsequent S2 (nicotine, lOyM), S3 
(buffer) and S4 (K+, 20mM) pulses were with drugs made up in the DH|3E 
buffer.
The effect of the AChE inhibitors on ACh release was studied, 
where the drug was either administered as a discrete pulse (S2) or 
continuously in the buffer, introduced 15 min after the SI pulse. 
BW284C51 was used at a concentration of lyM which was the rvwYAtAuM 
inhibition of AChE activity (see section 4.3.3.2.) and was the 
concentration used in the electrophysiological studies (see section
6.3.2.). Physostigmine (lyM) was used as a direct comparison with 
BW284C51. THA was used at 20yM as this was the reported IC50 at the 
nAChR (Perry et al., 1988).
Ca++ dependence was studied as described above, except the 
synaptosomes from the gradient were washed and superfused with 
Ca++-free buffer (where the CaC^ in the Krebs buffer had been 
replaced with NaCl). Pulses of drug (either nicotine (lOyM), K+
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(20mM) or buffer, made in Ca++-free buffer) were administered at 30 
min intervals after the 40 min washout period. Ca++ was introduced 
15 min after S2 and subsequent stimulations were with drugs made in 
Krebs buffer.
5.3. RESULTS AND DISCUSSION
5.3.1. Calcium dependency
In the absence of Ca++ both basal and evoked ACh release were 
reduced compared to that in the presence of Ca++, see fig. 5.1 and 
table 5.1. The slight increase in basal release with > in the
absence of Ca++ (fig. 5.1) could be due to mobilisation of internal 
Ca++ stores as suggested by Rowell & Winkler (1984). In the presence 
of Ca++, basal release returns to 'normal', see fig. 4.12.
Table 5.1 shows that the air bubble effect was not Ca++ 
dependent, as Ca++ had no effect on the level of tritium released by 
a pulse of Krebs buffer, adding to the suggestion that this response 
was a result of a mechanical and not a physiological process.
After the air bubble effect had been deducted, the ratio of 
-Ca++ (nicotine)/+Ca++ (nicotine) was approximately 36% indicating 
that nicotine evoked ACh release was 64% dependent on exogenous Ca++. 
A similar ratio of K+ evoked release showed that response was 65% 
dependent on Ca++.
This Ca++ dependency of nicotine- and K+-evoked ACh release 
indicates that the superfusion system is monitoring a physiological 
response and is consistent with other reports. Rowell & Winkler 
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Fig. 5.1. A superfusion profile shoving the effect of Ca on 
evoked ACh release. The synaptosomes were subjected to successive 
stimulations with nicotine (10pM; SI, S3) and K+ (20mM; S2, S4).
Ca++ was introduced into the system 15 min after the S2 pulse, f 
Indicates pulse arriving at the synaptosomes. Numbers in brackets 
are fmol ACh released/mg protein.
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PULSE NICOTINE K+ KREBS
lOyM 20mM BUFFER
-Ca++ 157.1* 188.0* 102.2
± 2.5 ± 2.3 ± 1.7
+Ca++ 255.1 348.5 101.4
± 2.7 ± 2.7
H-H
Table 5.1. The effect of Ca++ on evoked ACh release. Values are
fmoles ACh released/mg protein, n=8, before subtraction of air bubble 
effect. Significantly different from the response in the presence of 
Ca++, * p<0.001.
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dependent on the anion. Nicotine- and K+-evoked dopamine release 
from striatal synaptosomes was approximately 62% dependent on 
exogenous Ca++ (Rapier et al., 1988).
5.3.2. Nicotine-evoked acetylcholine release
5.3.2.1. Nicotine concentration
To check for variation between chambers and experiments a SI 
pulse of lOpM nicotine was consistently given. However, a tendency 
for variation between chambers was minimal in the system used as the 
response to lOyM nicotine (SI) was constant throughout these 
experiments and with those in sections 4.3.9., 5.3.3. and 5.3.4.
The effect of nicotine concentration on ACh release was studied 
by varying the concentration in the S2 pulse, see table 5.2. The 
effect due to air bubble was routinely determined in a S3 pulse of 
Krebs buffer, which was then deducted from the S2 value to obtain the 
response to drug. To ensure that the air bubble effect did not vary 
throughout the experiment buffer pulses were given as S2, S3 and S4 
(see table 5.2, OyM nicotine). The response to air bubble was 
constant (37% of the SI), indicating a mechanical process, confirming 
the validity of using the S3 buffer value to correct the S2 drug 
response.
As seen in table 5.2, there is a decrease in response with 
repetitive stimulation with lOyM nicotine such that S2/S1 (after 
deduction of the air bubble effect) = 85.5%. This suggests a 
reduction in synaptosome responsiveness with time and similar 
decreases with repetitive stimulations of drug was seen in section















0 284.5 107.1 105.0 106.0 -
(n=4) ± 2.3 ± 1.8 ± 2.0 ± 1.5 
(Krebs buffer)
1 280.6 120.7 105.8 345.0 8.5%
(n=6) ± 1.9 ± 2.2 ± 1.8 ± 3.1
3 276.1 203.0 104.9 340.8 57.3%
(n=3) ± 2.7 ± 1.5 ± 1.5 ± 3.0
10 284.1 259.2 108.8 340.1 85.8%
(n=6) ± 3.8 ± 2.1 ± 1.9 ± 2.6
30 278.1 282.1 107.9 340.0 102.4%
(n=4) ± 1.4 ± 2.9 ± 1.6 ± 3.5
100 282.3 220.2 108.7 341.6 64.2%
(n»5) ± 2.1 ± 2.4 ± 1.5 ± 3.3
Table 5.2. The effect of nicotine concentration on ACh release.
Nicotine concentration was varied (1-lOOyM) in the S2 pulse. Values
are fmoles ACh released/mg protein ± SEM. The S2/S1 ratio was 
calculated after deduction of the S3 buffer pulse.
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with lOyM ANTX (S2/S1 = 90%).
Nicotine-evoked ACh release increased in a dose-dependent manner 
reaching a maximum response at 30yM, see fig. 5.2. The decrease in 
release at higher (lOOyM) concentrations is unusual and difficult to 
interpret. If at this higher concentration the receptor had become 
desensitized, ACh release would be expected to reach a maximum and 
then plateau. A similar dose related effect on transmitter release, 
from brain slices, was seen by Lapchak et al., (1989) using a 
nicotinic agonist, methylcarbamylcholine.
A direct linear plot of ACh release (after deduction of the air
bubble effect) against nicotine concentration, not shown, gave an
EC50 (concentration to give half maximal effect) of 5yM and a Vmax
(maximum effect) of 136.3±7.1 fmol ACh released/20s/mg protein. In
section 3.3.3.3.2B, ANTX evoked ACh release, from sucrose
isolated synaptosomes, had an EC50 of 7.5yM similar to that of
nicotine reported here. However, the Vmax of the ANTX
evoked response was 23.9±3 fmol ACh released/40s/mg protein which was
approximately six fold lower than that reported here. This increase
in Vmax suggests that the Percoll method of isolating synaptosomes
produces a purer and more responsive preparation for studying
transmitter release than the sucrose method and is consistent with
3
the six fold higher levels of [ H]Ch uptake (see fig. 4.7).
5.3.2.2. The effect of DH(5E
The nicotinic nature of this evoked release was studied in the 























Nicotine concentra t ion  (/xM)
Fig. 5.2. The effect of nicotine concentration on ACh release.
The nicotine concentration was varied in the S2 pulse.
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DHpE SI S2 S3 S4 S2/S1
lOyM NICOTINE NICOTINE KREBS K+
lOpM lOyM BUFFER 20mM
- 281.1 248.4 103.8 346.5 81.6%
± 2.2 ± 2.7 ± 1.2 ± 2.2
+ 285.0 174.3* 108.8 342.0 37.2%
± 2.0 ± 3.1 ± 1.5 ± 2.1
Table 5.3. The effect of DH|3E on nicotine evoked ACh release. DH0E
(10pM) was introduced 15 min after SI. Values are expressed as fmol 
ACh released/mg protein ± SEM of 10 chambers. S2/S1 ratio was 
determined after subtraction of the buffer pulse. Significantly 
different from control (no DH0E) * p<0.001.
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Nicotine-evoked ACh release, in the presence of DHflE, was 45% of 
the control (no DHflE). This reduction (55%) in ACh release by DHpE 
suggests that the response was via a nAChR. A similar inhibition of 
nicotine evoked transmitter release by DHflE was reported by Wonnacott 
et al., (1988) for both ACh and GABA release from hippocampal 
synaptosomes. DH0E inhibited ANTX induced ACh release by a 
similar amount, 50%, see section 3.3.3.3.1. As expected DHfSE had no 
effect on K+ evoked ACh as this depolarisation is not via the nAChR. 
The air bubble effect was not affected by DH$E which was as expected 
as this is a mechanical response.
5.3.3. Effect of acetylcholinesterase inhibitors on release
5.3.3.1. AChE inhibitors as stimulators of ACh release
Any stimulatory effects of the AChE inhibitors: BW284C51,
physostigmine and THA, on ACh release were examined by administering 
the drugs as a S2 pulse, see table 5.4.
Responses to THA were comparable to those produced by Krebs 
buffer alone. Thus THA had little or no effect on ACh release.
Perry et al., (1988) reported that 20yM was the IC50 for THA binding 
to the nicotinic receptor. However, at this concentration THA may 
bind to the receptor but have no stimulatory effect on ACh release, 
for example by binding to the 0 subunit of the receptor and not the 
agonist binding a subunit (see section 1.3.2.3.).
Both BW284C51 and physostigmine elicited substantial ACh 
release. Although the response to BW284C51 was lower than that 
produced by nicotine, physostigmine effects were the same. The 
enzymic extraction procedure, described in section 3.3.3.1.4., showed 




























































Table 5.4. The effect of AChE inhibitors as stimulators 
of ACh release. BW284C51 (lyM), physostigmine (lyM) or THA (20yM) 
were introduced as a S2 pulse. Values are fmol ACh released/mg 
protein ± SEM. S2/S1 ratios were determined after the deduction of 
the buffer pulse. Significantly different from the control (lOyM 
nicotine), * p<0.001.
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superfusion samples was ACh and so there was little, or no, ACh 
hydrolysis. Thus the increase in ACh levels, above basal, in the 
presence of these AChE inhibitors was not as a result of preventing 
ACh hydrolysis.
BW284C51 stimulated release was 82% of the response to nicotine. 
This suggests that BW284C51 could be interacting with the nAChR by 
acting as a nicotinic agonist. However, Mizobe & Livett (1982) 
reported that lyM BV284C51 exhibited only AChE inhibitory action but 
at higher concentrations BW284C51 did appear to interact with the 
nAChR of chromaffin cell cultures. Thus lyM BW284C51 may be 
eliciting ACh release not through the nAChR but via some other 
mechanism perhaps by interacting with ion channels causing 
depolarisation.
Physostigmine-evoked ACh release was 103% of that produced by 
nicotine, suggesting there was interaction with the nAChR. This 
finding is contrary to that of Mizobe & Livett (1982) who reported 
that physostigmine (at concentrations of lyM or less) had only AChE 
inhibitory actions in chromaffin cell cultures. However, the 
suggestion that physostigmine interacts with the nAChR is consistent 
with the findings of Shaw et al., (1985) who observed that 
physostigmine acted as a nicotinic agonist at the frog muscle nAChR 
at concentrations as low as 0.5yM.
5.3.3.2. AChE inhibitor's effect on basal and evoked ACh release
The effect of the prolonged presence of the AChE inhibitors in 
the washing buffer, introduced 15 min after SI, on basal release of 































Fig, 5.3. Superfusion profiles of the effect of Krebs buffer, 
containing AChE inhibitors, on basal release. AChE inhibitor was 
introduced into the washing Krebs buffer 15 min after the SI pulse. 
Physostigmine (lyM, A); Krebs buffer (♦); BW284C51 (lyM,V); THA 
(20yM,#).
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ACh release was shown in table 5.5. Physostigmine (lyM) appeared to 
slightly increase basal ACh release compared to the normal Krebs 
washing buffer whereas the baseline with BW284C51 (lyM) was 
approximately 70% of that of Krebs buffer. However, THA (20yM) 
dramatically dropped the baseline to 50% of that of the control 
(Krebs buffer alone).
BW284C51 appeared to have little or no effect on nicotine or 
K+-evoked ACh release, despite the 30% drop in basal release, 
indicating that BW284C51 (lyM) does not interfere with either the 
nicotine binding site nor K+ depolarisation. The mode of action of 
this AChE inhibitor is unclear but the reduction in basal release 
could be due to interaction with ion channels other than those 
involved in K+ depolarisation.
Physostigmine enhanced the nicotine response by about 30%, which 
is consistent with its own ability to release transmitter as shown by 
the increase in basal release (fig. 5.3) and by administration of a 
pulse of lyM physostigmine (see table 5.4 and 5.5). Both nicotine 
and K+ responses were increased in the presence of lyM physostigmine 
which is consistent with the findings of Shaw et al., (1985) who 
reported that low yM concentrations of physostigmine interact with 
the nAChR evoking ACh release. Sadoshima et al., (1988) observed that 
at physostigmine concentrations of lOyM or greater this enhancement 
of ACh release was reduced in a dose dependent manner.
THA had a dramatic effect on basal release with a corresponding 
reduction in nicotine- and K+-evoked ACh release. Stevens & Cotman 
(1987) and Rogawski (1987) reported that THA blocked specific K+ (1^ ) 
currents and also voltage dependent Na+ channels (Rogawski, 1987) and
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BUFFER SI S2 S3 S4 S2/S1 S4/S1
NICOTINE NICOTINE BUFFER K+
lOyM lOyM 20mM
KREBS 308.6 277.1 108.3 379.4 86.5% 122.9%
(CONTROL) ±4.0 ±4.1 ±2.0 ±4.4
(n=6)
BW284C51 299.8 245.5 102.9 364.3 81.9% 121.5%
lyM ±4.2 ±2.3 ±3.5 ±4.6
(n=4)
PHYSOSTIGMINE 316.4 351.3* 283.3 423.6* 111% 133.9%
lyM ±5.6 ±3.7 ±4.4 ±3.5
(n=5)
THA 291.3 113.4* 105.3 138.1* 38.9% 47.4%
20yM ±4.4 ±3.1 ±3.7 ±2.9
(n=3)
Table 5.5. The effect of AChE inhibitors on evoked ACh release. The
AChE inhibitors were introduced into the washing buffer 15 min after 
SI. Subsequent pulses (S2-S4) were with drug made up in buffer 
containing AChE inhibitor. Values are expressed in fmol ACh 
released/mg protein and are the mean ± SEM. The S2/S1 and S4/S1 
ratios were determined before deduction of the buffer pulse. 
Significantly different from the control (Krebs buffer), * p<0.001.
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this could explain the reduction in basal release. The effect of THA 
on evoked ACh release is difficult to interpret as the contribution 
of the action of THA on the ion channels to the reduction in nicotine 
stimulated ACh release needs to be determined. Perry et al., (1988) 
reported that 20yM was the IC50 for THA binding to the nAChR but when 
THA (20pM) was given as a discrete pulse (table 5.4) there was little 
or no enhanced ACh release, above the air bubble effect. Until the 
mode of action of THA has been determined then the effect of THA on 
evoked ACh release can not be elucidated.
5.4 SUMMARY
The Percoll fraction F4 is enriched in synaptosomes which are
3
cholinergic in nature, as shown by the markers ChAT and [ H]Ch uptake 
(section 4.3.4.2. and 4.3.5., respectively). Nicotine stimulated 
ACh release from these synaptosomes, in a dose dependent manner, 
which was blocked by the antagonist DHpE, suggesting that evoked 
release was via a nAChR. This nicotine induced ACh release was 
dependent on exogenous Ca++, indicating that the response to the drug 
was a physiological process.
The nAChR needs to be fully characterised (using agonists:
DMPP, ANTX and antagonists: d-tubocurarine, hexamethonium, 
mecamylamine) before the mAChR can be studied (using agonists: 
muscarine, oxotremorine and antagonists: atropine and scopolamine). 
Having determined how each receptor contributes to ACh release, under 
known conditions, the effect of ACh on its own release could be 
examined. Thus the self regulation of ACh at the hippocampal nerve 
terminal could be determined.
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From these experiments, section 5.3.3, it is clear that the 
drugs BW284C51, physostigmine and THA not only have AChE inhibitory 
action but also effect ACh release from hippocampal synaptosomes. 
BW284C51 (lyM) has a stimulatory effect on ACh release when 
administered as a discrete pulse. However, prolonged application of 
BW284C51 decreases the basal release by 302, see section 5.3.3.2., 
but has little or no effect on nicotine-evoked ACh release, 
suggesting that BW284C51 does not bind to the nAChR. The reduction 
in basal release and the stimulatory response of BW284C51 suggests 
that this AChE inhibitor may interact with other ion channels.
Physostigmine increases both basal and nicotine-evoked ACh 
release, which is consistent with physostigmine interacting with the 
nAChR. To examine if physostigmine stimulated ACh release is via the 
nAChR, experiments should be repeated in the presence of the 
antagonist DH|3E.
The AChE inhibitor THA had little or no stimulatory effect on 
ACh release, when given as a discrete pulse, but reduced the basal 
release by 502 when administered for a prolonged period, see section
5.3.3. and fig. 5.3. The decrease in baseline is consistent with 
reports that THA interacts with ion channels, the profile looks 
similar to that obtained in Ca++ free buffer (fig. 5.1), and so the 
effects, if any, of THA on the nicotine-evoked ACh release, via the 
nAChR, was masked. However, 20yM THA is much higher than the plasma 
levels obtained from patients treated for SDAT with this drug, thus 
the therapeutic relevance of this ion channel effect is unclear. 
Experiments at lower THA levels (0.02-lyM in plasma, Park et al., 
1986) are needed to ascertain whether these effects are present at
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therapeutic levels. If so then the ion channels involved in this 
phenomenon can be determined using channel blockers, for example: mM 
concentrations of tetraethylammonium, 4-aminopyridine and barium 
block Ca++ independent K+ currents. To examine if the THA action 
involves the blockade of Ca++ ions the Ca++ ionophore A23187 could be 
used to circumvent endogenous Ca++ channels. Having determined the 
THA effects in the synaptosome then the response in more complex 
models may be easier to interpret and so the therapeutic benefits of 
this drug, in the treatment of SDAT, can be better evaluated.
CHAPTER 6. AN ELECTROPHYSIOLOGICAL STUDY OF THE NICOTINIC
ACETYLCHOLINE RECEPTOR IN RAT HIPPOCAMPAL SLICES.
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6.1. INTRODUCTION
Having studied the nAChR in the synaptosome preparation, the 
presence of functional nAChRs in a more complex model, the 
hippocampal slice, was assessed in preliminary electrophysiological 
studies using evoked field potentials.
6.1.1. The hippocampus as a model for studying long term 
potentiation
Electrophysiological recordings from brain slices was first 
developed by Yamamoto & Mcllwain (1966) who showed that isolated 
slices of prepyriform cortex could be maintained in vitro and still 
exhibit electrical activity comparable to that obtained from the 
intact brain. Skrede & Westgaard (1971) were instrumental in 
establishing the hippocampus as a candidate for brain slice studies. 
The hippocampus is ideally suited for such studies because of its 
laminated geometry allowing the consistent positioning of electrodes 
into the area of interest, see fig. 6.1.
The observation that a change in synaptic efficacy can be seen 
at the hippocampal synapse, both in vivo and in vitro, provided a 
strong impetus for the continued use of this brain slice preparation 
to study the memory-related phenomenon, long term potentiation (LTP). 
LTP is characterised by a stable, relatively long lasting increase in 
the magnitude of the postsynaptic response to a constant afferent 










Fig. 6.1. A schematic diagram of a hippocampal slice. This 
depicts the laminar pyramidal cells (CA1, CA2, CA3) of the pyramidal 
layer (PYR) and the positions of the stimulating and recording 
electrodes. F, fimbria; DG, dentate gyrus.
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LTP is dependent on synaptic transmission and the density of 
innervation to a given neurone or neuronal population. There is, 
however, some controversy as to whether LTP is maintained by a 
presynaptic (more transmitter release; Sastry, 1982; Bliss et al., 
1986) or a postsynaptic mechanism (greater sensitivity of the target 
membrane; Lynch & Baudry, 1984; Muller et al., 1988). Davies et al. 
(1989) found that the mechanism is presynaptic for the first half 
hour and gradually the postsynaptic membrane becomes more sensitive, 
such that with time an increased sensitivity of the postsynaptic 
membrane grows so that LTP is maintained by a postsynaptic mechanism.
This complicated mechanism fits with other recent observations 
of Kauer et al., (1988) who showed that LTP had two temporal phases: 
a transient phase which lasted for 30 min (the same as the 
presynaptic response of Davies et al., 1989) which could be evoked in 
isolation by applying transmitter directly into the synapses.
Malinow et al., (1988) showed that in the presence of kinase 
inhibitors the transient phase of LTP was still evoked but the 
maintained phase failed to develop, thus suggesting that the 
maintained component of LTP results from an increased sensitivity of 
postsynaptic receptors to neurotransmitter resulting from some kinase 
activity (for review see Stevens, 1989).
LTP in the hippocampus is widely studied as the mechanisms 
involved in its induction and maintenance are believed to underlie 
fundamental properties of learning and memory in vertebrates (Bliss & 
Lynch, 1988).
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6.1.2. The nicotinic acetylcholine receptor in the hippocampus
The electrophysiological evidence for a functional nAChR, in the 
hippocampus, has been much debated. Bird & Aghajanian (1976) 
reported that muscarine and other muscarinic agonists caused 
postsynaptic excitation at concentrations lover than those needed for 
ACh to elicit a response. This excitation was blocked by both 
scopolamine (a mAChR antagonist) and DH(3E (a nAChR antagonist). From 
this they deduced that there was a single receptor type exhibiting 
both nicotinic and muscarinic effects and not two independent 
receptor types due to the crossover effect of DH£E on muscarinic 
excitation.
Haas (1982) and Cole & Nicoll (1984a) reported that carbachol 
(which acts differentially at both the nAChR and mAChR) caused 
excitation similar to that of ACh and that this response was blocked 
by the muscarinic antagonist atropine. Haas made no conclusion on 
whether the effect was purely muscarinic, even though the response 
was blocked by atropine. Cole & Nicoll suggested that only mAChR and 
not nAChR or a nicotinic/muscarinic receptor was involved in the 
depolarisation as DHfSE had no effect on the carbachol excitation.
The conclusion of Cole & Nicoll was in support of the findings of 
Segal (1978) who also reported the existence of only mAChR actions.
Rovira et al., (1983) did detect a nicotinic input associated 
with the CA1 pyramidal cells of the hippocampus (see fig. 6.1) and 
observed a clear cut distinction between mAChR and nAChR actions. 
Muscarine depressed the amplitude of the evoked negative field 
whereas nicotine increased the potential (especially its duration) 
and is consistent with presynaptic nAChR facilitating transmitter
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release. There have been several reports to support the existence of 
distinct nicotinic and muscarinic receptors where the actions of 
nicotine are blocked by nicotinic antagonists and not muscarinic 
antagonists, and nicotinic antagonists are ineffective against 
muscarinic agonists (McLennan & Hicks, 1978; Bradley & Lucy, 1983; 
Takagi, 1984).
cDNA cloning techniques have revealed at least three subtypes of 
neuronal nAChR in the brain which are functionally expressed and 
structurally related, but different, to that found in muscle (for a 
review see Steinbach & Ifune, 1989; this report section 1.3.2.).
6.1.3. Practical aspects of electrophysiology
In order to study the nAChR in the hippocampal slice the 
following practical aspects of electrophysiology have to be 
considered.
6.1.3.1. Types of recordings
There are three types of electrophysiological recordings from 
which data can be obtained to determine functional receptor activity:
1. Extracellular recordings are the least specific as they 
monitor the transmitter effects of a field of neurones 
(Bird & Aghajanian, 1976; Vidal & Changeux, 1989; this 
report).
2. Intracellular recordings monitor the excitatory or 
inhibitory effects of a transmitter or drug on a single 
neurone (Haas, 1982; Cole & Nicoll, 1983, 1984a, b; Egan 
& North, 1986).
3. Patch clamp recordings which monitor the transmitter
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effects at a single receptor channel (Aracava et 
al., 1987).
6.1.3.2. The tissue chamber
The tissue chamber provides the necessary environment for 
bathing the slice in medium. The medium contains a balanced salt 
content and substrate source, usually glucose, also the appropriate 
oxygen and carbon dioxide levels for slice survival. The chamber 
acts as a mechanical support for the slice and has illumination for 
placing the electrodes. The chamber is temperature controlled to 
provide optimum conditions for electrical activity. It also has 
provisions for changing the chemical composition of the medium, if 
required.
There are numerous designs for the tissue chamber but four of 
the most common are depicted in fig. 6.2 and are as follows:
1. Superfused chambers (fig. 6.2a) where the tissue rests at 
the medium/gas interface. The medium is continually 
flowing through the system.
2. Plate chambers (fig. 6.2b) which are like the superfused 
chamber except that there is no pool of medium. This has 
one advantage over the superfused model-in that there is 
reduced dead volume when changing the medium.
3. Static chambers (fig. 6.2c) where the tissue is at the 
medium/gas interface but has a static pool of medium that 
could be changed by a push-pull pump. The advantage of 
this model is that it maintains the ultrastructure of the 
tissue which may become disturbed by flowing medium.
4. Submerged chambers (fig. 6.2d) where the tissue is





Fig. 6.2. Schematic diagrams
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four of the most commonly used
tissue chambers.
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submerged in the medium. This needs moderate flow rates 
of veil oxygenated medium to maintain optimal 
physiological conditions of the tissue. Submerged chambers 
are used when studying alterations in medium composition 
or when delivering drugs as it has two surfaces for
diffusion into the tissue. A submerged chamber was used
in the experiments reported in this thesis.
6.1.3.3. Electrodes
A variety of recording and stimulating electrodes have been 
successfully used in brain slice experiments.
6.1.3.3.1. Recording electrodes
Metal or glass micropipettes are adequate for recording 
extracellular field potentials or intracellular readings.
Electrolyte filled micropipettes, used in this study, are commonly 
used for recording field potentials. The disadvantage of finely 
drawn micropipettes is the difficulty of seeing them while 
manipulating them relative to the slice. The addition of dye (such 
as Fast Green) into the electrolyte aids visualisation and marks the 
location of the recording electrode but may be associated with a 
certain amount of toxicity to the tissue. Thus it is important to 




The small distance between the stimulating and recording 
electrodes compound the problem of stimulus artefact (fig. 6.3) when 
monopolar stimulating leads are employed. Use of a twisted pair 
stimulating electrodes, used in this study, or concentric bipolar 
electrodes reduce the stimulus artefact.
6.1.4. Factors to consider for reproducibility
In order to produce consistent slices and responses a number of 
factors have to be considered:
6.1.4.1. Presacrifice condition of the animal
The state of the animal just prior to sacrifice can affect slice 
experiments. Harris & Teyler (1983) showed that the time of 
sacrifice relative to the animal's circadian rhythm, affects the 
induction of LTP in the slice. Therefore animals of the same 
species, sex and age and the time of sacrifice should be consistent.
Presacrifice stressors might also confound the experiments as 
Foy et al., (1985) reported, LTP could not be elicited in hippocampal 
CA1 pyramidal cells from rats that were given a series of tail 
pinches 30 min prior to sacrifice. This effect was significantly 
correlated to corticosterone levels.
6.1.4.2. Slice preparation
The slice preparation time is an important factor in maintaining 









Fig. 6.3. A typical waveform. This waveform was produced by 
nicotine (lOOyM) in the presence of BW284C51 (lyM) showing the 
primary (1°) and secondary (2°) potential. A: amplitude, Is
integral, L: latency, S: stimulus artefact.
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The older the animal the harder the skull becomes which often 
breaks in pieces rather than along the suture lines. The meninges 
also appear tougher thus increasing the handling and time needed to 
remove the brain. The tissue should be removed with minimal handling 
without applying obvious physical stress and keeping the tissue 
moist. Extended preparation time and excessive handling often result 
in multiple population spikes following single pulse stimulation in 
the CA1 area (DiScenna, 1987). The average time of slicing for this 
work was 10 min from the time of sacrifice to slices being placed in 
the recovery bath (see section 6.2.1.).
6.1.4.3. Slice orientation
Slices at an angle perpendicular to the septo-temporal axis are 
generally used producing hippocampal slices like the one depicted in 
fig. 6.1. This angle can shift along the length of the hippocampus 
probably due to differences in the distribution pattern of intrinsic 
hippocampal fibres (Swanson et al., 1978).
It is best to take slices from the same septo-temporal segment 
since differences in the excitability of dorsal and ventral regions 
of the hippocampus have been noted (Mizuno et al., 1984).
6.1.4.4. Slice thickness
The slice has a zone 50-100ym at the cut edge in which cells are 
badly damaged (Misgeld & Froetscher, 1982). Thus this outer region 
should be considered dead tissue and it is not possible to obtain 
good electrophysiological responses from the top 50ym+ of the slice 
(Bak et al.y 1980).
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On the other hand, excessively thick slices are unable to 
maintain adequate oxygenation and substrate supply which occurs at 
approximately 500ym. The isolated hippocampal slice is devoid of a 
functional vascular network and so is dependent upon the superfusing 
oxygenated buffer for delivery of nutrients and gases, as well as the 
removal of waste products. Oxygen diffuses into slices at the 
medium/gas interface in chambers other than the submerged model. A 
thickness of 400ym, used in this study, represents a suitable 
distance through which waste products and nutrients can diffuse to 
preserve function (Tseng et al., 1987).
Slices with nicks, torn or frayed edges, smeared or widened cell 
fields, or swollen, thick or uneven appearance should be avoided. 
Though these slices may initially provide acceptable responses, they 
seldom demonstrate adequate stability resulting in wasted effort 
(DiScenna, 1987). Slices with smooth edges, a clear translucent 
appearance with even thickness and crisp well-defined cell fields 
should be used.
6.1.4.5. Electrode placement
One advantage of slice preparations, over intact structures, is 
the ability to visualise cell body and afferent fibre zones.
Therefore electrode location can be optimised to produce consistent 
responses and response range. The optimum recording site is half way 
through the slice.
Many hippocampal afferents terminate in a laminar pattern in the 
dendritic fields of the pyramidal and granule cells (Steward, 1976; 
see fig. 6.1). This laminar pattern can be used for consistent
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placement of the electrodes thus increasing the probability of 
studying homogenous afferent populations.
6.2. EXPERIMENTAL METHODS AND APPARATUS
A 2% agar solution was made and allowed to cool before use. A 
bicarbonate buffer (composed of, mM: NaCl, 124; NaHCO^, 26; KC1, 5;
MgSO^, 2; K^PO^, 1.25; CaC^* 2; glucose, 10) was continuously 
gassed with 95% oxygen/5% carbon dioxide.
6.2.1. Preparation of hippocampal slices
A male Hooded Listar rat was anaesthetised with diethyl ether 
and then decapitated. The brain was rapidy removed and placed on a 
petri dish containing some bicarbonate buffer. The cerebellum was 
removed and the brain cut sagittally along the longitudinal 
fasiculus. The neocortex, overlaying the hippocampus, was removed 
before the tissue was placed on the stage of the vibratome and stuck 
to an agar block such that the dorsal surface of hippocampus faced 
the blade and the medial aspect was uppermost. The stage was placed 
in the vibratome reservoir containing continuously gassed bicarbonate 
buffer. Slices, 400ym thick, were cut from the dorsal hippocampus 
which were then separated from the underlying thalamus before being 
transferred to a recovery bath. The recovery bath contained 
continuously gassed bicarbonate buffer and the slices remained here 
for 2 hr to recover electrical activity and overcame the effects of 
hypoxia (Reid et al., 1984).
194
6.2.2. Preparation of the apparatus
Meanwhile, the tissue chamber was prepared by continual 
superfusion with distilled water with the temperature controller set 
at 32°C. The temperature of 32°C is a compromise between being too 
high, causing greater metabolic demands on the slice and generating 
spontaneous activity, and being too low thus reducing metabolic 
activity (Schiff & Somjen, 1985). The tissue slice is easier to keep 
alive below 37°C. Once the chamber was at 32°C the distilled water 
was replaced with continuously gassed bicarbonate buffer at a flow 
rate of 2ml/min.
The Neurolog equipment, through which the electrical stimulus 
was administered and the response captured, amplified and displayed 
on a cathode ray oscilloscope, was switched on to warm up.
A glass micropipette recording electrode was made using a 
microelectrode puller and filled with 4M NaCl. Only micropipettes 
with an electrical resistance of 5-10 Ohm were used.
After the 2 hr recovery period a hippocampal slice was placed in 
the submerged tissue chamber. Using micromanipulators, the recording 
electrode was placed in the CA1 area and the stimulating electrode 
(SNEX-200, Clark Electomedical) was placed in the CA2 area 
(see fig. 6.1).
Stimulation of the CA2 area with square waves of 200-400yA,
0.1-0.2ms produce population potentials of l-4mV amplitude. It is 
important not to stimulate the pathway at too high a frequency, 
otherwise short term potentiation may occur (Schurr et al., 1986). 
Thus a stimulation frequency of 0.1-0.2Hz was used.
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The threshold and maximum stimulus parameters for the production 
of a population potential were determined and a stimulus current 
which produced 85-95% of the maximum observed potential was selected.
This waveform was averaged, 8 sweeps per average, every 15 min 
for 3/4-1 hr to ensure the stability of the recording. Only 
pyramidal cells with an amplitude of 2-4mV were used in this study.
A typical waveform is shown in fig. 6.3, when only bicarbonate buffer 
was present there was no secondary potential.
6.2.3. Preparation of test drugs
Nicotine (l-100yM) or the AChE inhibitor BW284C51 (l-30yM) were 
made up in gassed bicarbonate buffer and substituted for the buffer 
superfusing the tissue slice. The effect of these drugs on the 
development of a secondary potential was monitored on the 
oscilloscope and averages were taken every 15 min. Successive 
concentrations of nicotine or BW284C51 were tested in an accumulative 
manner by increasing the concentration of the drug in the superfusing 
buffer, changes in the medium were made after the 15 min averaging. 
After the drug effects had been determined the response could be 
returned to normal by replacing the superfusing medium with 
bicarbonate buffer or the effect of antagonist (DH£E, lOyM; 
scopolamine, lyM) could be studied.
6.2.4. Types of measurements obtained
The measurements that can be obtained from a waveform are 
depicted in fig. 6.3 and are as follows:
1. LATENCY - the time delay between the stimulus and 
recording the potential, which is determined by the
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conduction velocity of the stimulated fibres and the 
synaptic delay at the pyramidal cells.
2. AMPLITUDE - a function of both the number and the time 
period over which neurones are activated.
3. INTEGRAL - a more accurate measure of the number of 
neurones activated since this represents the algebraic sum 
of the individual cell potentials. It was this 
measurement that was used to assess the effect of nicotine 
and other drugs on the hippocampal slice.
6.3. RESULTS AND DISCUSSION
Nicotine (l-100yM) had little or no effect on the amplitude or 
integral of the primary potential. In only one out of five 
experiments did lOOyM nicotine elicit a slight secondary potential, 
indicating that nicotine may be effective at higher concentrations. 
This was supported by Freund et al., (1988) who reported that nicotine 
elicited a secondary potential at a concentration of 800yM. However, 
such high concentrations are not thought to be physiologically 
relevant.
Cole & Nicoll (1983, 1984a, b) and Egan & North (1986) reported 
that ACh needed the presence of an AChE inhibitor (physostigmine, 
1-lOyM or neostigmine, 0.1-10yM) to elicit a potential response at 
concentrations of l-100yM. If there was no AChE inhibitor present 
then a 10-100 fold higher ACh concentration was required to achieve 
the same response.
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If the nicotinic effect is presynaptic, enhancing ACh release, 
as suggested by the superfusion data in this report then ACh 
hydrolysis by AChE would reduce the nicotine response recorded.
Vidal & Changeux (1989) reported that the nicotinic effect of ACh was 
observed only in the presence of physostigmine (1-lOyM). This 
suggests that an AChE inhibitor is needed in order to study the 
functional response of drugs at the nAChR. In this study the AChE 
inhibitor BW284C51 was used.
6.3.1. The effect of BW284C51
Fig. 6.4 shows that the development of a secondary potential 
increased with BW284C51 concentration. This suggests that BW284C51 
is blocking AChE activity resulting in an increase in ACh levels that 
elicit a secondary potential. At a concentration of 5yM or greater 
the secondary potential began to decrease and this could be due to a 
build up of ACh causing a negative feedback on its release via the 
presynaptic mAChR (see fig. 1.1). Thus ACh is no longer released and 
so the secondary potential decreases. Alternatively, the reduction 
in response could be due to receptor desensitisation where the 
receptor is no longer responsive to the stimulus.
The cholinergic nature of this secondary potential was examined 
by studying the effect of DH0E (the nAChR antagonist, 10yM) and 
scopolamine (the mAChR antagonist, lyM) on the response elicited in 
the presence of 3yM BV284C51, see fig. 6.4. DHfSE (lOyM) had little 
or no effect on the response elicited by 3yM BW284C51. Scopolamine 
(lyM) completely blocked the production of a secondary potential, 
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Fig. 6.4. The effect of BW284C51 concentration on the 
development of a secondary potential. BW284C51 concentration in the 
superfusing buffer was increased after the 15 min averaging and the 
integral of the secondary potential was recorded (▼). The effect of 
DHfSE (10yM,^) and scopolamine (lyM,A) on this secondary potential was 
also examined. (#) is the integral of the primary potential. Values 
are the means ± SEM, n=4.
199
6.3.2. The effect of nicotine
A BW284C51 concentration of lyM was used to study the effect of 
nicotine on ACh release. At this concentration a small secondary 
potential had developed (fig. 6.4 and 6.5) suggesting the AChE 
activity had been blocked, increasing ACh levels, but the BW284C51 
effects were not too great as to mask the response elicited by 
nicotine. Section 4.3.3.2. (fig. 4.4a) showed that lyM BW284C51 was 
sufficient to block 90% of the AChE activity in the SI supernatant of 
the hippocampal homogenate. The SI supernatant was used as it was 
more representative of the enzyme activity in the slice than any one 
of the fractions from the Percoll gradient. Mizobe & Livett (1982), 
in their study on the effect of AChE inhibitors on the nicotinic 
response to acetylcholine in cultured adrenal chromaffin cells, 
showed that lyM BW284C51 inhibited 85% of AChE activity. Thus the 
effect of nicotine concentration (l-100yM) on eliciting a secondary 
potential was studied in the presence of lyM BW284C51, assuming up to 
90% inhibition of AChE activity.
Nicotine, in the presence of BW284C51, showed a dose dependent 
increase in the secondary potential (fig. 6.5). The effect was 
approaching maximal at a nicotine concentration of lOOyM. DH|3E 
(lOyM) completely abolished the nicotine effect indicating that the 
response was via a nAChR. However, scopolamine (lyM) only reduced 
the secondary potential by 60%. This was less than expected because 
if the recorded postsynaptic effect is purely muscarinic then 
scopolamine should completely block the response elicited by nicotine 
and BW284C51. Nicotine has been reported to elicit the release of 
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Fig. 6.5. The effect of nicotine concentration on the 
development of a secondary potential. Nicotine concentration, in the 
presence of lyM BW284C51, was increased after the 15 min averaging 
and the integral of the secondary potential was recorded (▼). The 
effect of DHf3E (10yM,+) and scopolamine (lyM, A) on this secondary 
potential was also examined. (#) is the integral of the primary 
potential. Values are the mean ± SEM, n=3.
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(Wonnacott et al., 1988) and this could account for 40% of the 
nicotine evoked secondary potential not being blocked by the 
anticholinergic scopolamine.
6.4. SUMMARY
This preliminary work shows that there is a functionally active 
nAChR in the hippocampus. Experiments with the AChE inhibitor 
BW284C51 and the cholinergic antagonists DH|3E (nicotinic) and 
scopolamine (muscarinic) suggest a presynaptic nAChR and a 
postsynaptic mAChR localisation. The secondary potential measures 
the postsynaptic changes and the secondary potential produced by 
BW284C51 was blocked by scopolamine but DH$E had little or no effect, 
see fig. 6.4. Nicotine enhanced the secondary potential, this 
enhancement was blocked by DH0E whereas scopolamine had less effect, 
see fig. 6.5. However, prolonged nicotine stimulation, used in these 
experiments to construct the concentration curve, has been reported 
to cause desensitisation of the nAChR in intracellular recordings 
from rat locus coerulus (Egan & North, 1986) and this could explain 
the lack of a postsynaptic nAChR effect.
Extended nicotine stimulation, in the superfusion buffer, of the 
electrophysiological work was necessary to ensure complete diffusion 
of the drug through the slice. Long washout periods are also 
required (1-2 hr) to ensure that all the drug has been removed and so 
repetitive stimulations, returning to baseline between each drug 
administration, are not easily achieved. Superfusion experiments 
with synaptosomes need only short drug stimulations, 20s, as the 
preparation is considered to be a monolayer in the chamber.
Repetitive stimulations are easier to administer to synaptosomes as
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response returns to baseline 10-20 min after the drug pulse.
However, synaptosomes have no neuronal interconnections which are 
present in the slice and so are less representative of in vivo 
responses.
Further experiments to fully characterise this nicotinic 
response are needed and the use of agonists and antagonists for other 
transmitters would ascertain whether the development of the secondary 
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